Cerebrospinal fluid biochemical studies in patients with Parkinson's disease: Toward a potential search for biomarkers for this disease

Frontiers in Cellular Neuroscience

Volumn 8, Issue November, 2014, Pages

  Jiménez Jiménez, Félix J ^a   Alonso Navarro, Hortensia ^a   García Martín, Elena ^b,c   Agúndez, José A G ^b,c  

^a Uro Ginecológico   (Spain)

^b UNIVERSITY OF EXTREMADURA   (Spain)

^c AMGenomics   (Spain)

Author keywords

Alpha synuclein; Beta amyloid; Biological markers; Cerebrospinal fluid; Neurotransmitters; Oxidative stress; Parkinson's disease; Tau protein

Indexed keywords

4 AMINOBUTYRIC ACID; ACETYLCHOLINE; ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN[1-42]; ASPARTIC ACID; BETA ENDORPHIN; BIOLOGICAL MARKER; BIOPTERIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CHOLECYSTOKININ OCTAPEPTIDE; CYTOKINE; DIHYDROXYPHENYLACETIC ACID; DOPAMINE; DOPAMINE BETA MONOOXYGENASE; DYNORPHIN[1-8]; EPIDERMAL GROWTH FACTOR; HOMOVANILLIC ACID; LEUCINE ENKEPHALIN; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; METENKEPHALIN; NEUROPEPTIDE; NORADRENALIN; SEROTONIN; SOMATOMEDIN C; SOMATOSTATIN; TRANSFORMING GROWTH FACTOR; TRANSITION ELEMENT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; BLOOD BRAIN BARRIER; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; COGNITIVE DEFECT; DEMENTIA; DISEASE SEVERITY; DRUG CEREBROSPINAL FLUID LEVEL; HUMAN; LIPID PEROXIDATION; NEUROIMAGING; NEUROMODULATION; NEUROTRANSMISSION; NIGRONEOSTRIATAL SYSTEM; OXIDATIVE STRESS; PARKINSON DISEASE; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 84922712285     PISSN: 16625102     EISSN: None     Source Type: Journal    
DOI: 10.3389/fncel.2014.00369     Document Type: Article

References (348)

1. Abbott, R. J., Pye, I. F., and Nahorski, S. R. (1982). CSF and plasma GABA levels in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 45, 253-256. doi: 10.1136/jnnp.45.3.253.
2. Abe, T., Isobe, C., Murata, T., Sato, C., and Tohgi, H. (2003). Alteration of 8-hydroxyguanosine concentrations in the cerebrospinal fluid and serum from patients with Parkinson's disease. Neurosci. Lett. 336, 105-108. doi: 10.1016/S0304-3940(02)01259-4.
3. Aerts, M. B., Esselink, R. A., Abdo, W. F., Bloem, B. R., and Verbeek, M. M. (2012). CSF α-synuclein does not differentiate between parkinsonian disorders. Neurobiol. Aging 33, 430e1-e3. doi: 10.1016/j.neurobiolaging.2010.12.001.
4. Aerts, M. B., Esselink, R. A., Bloem, B. R., and Verbeek, M. M. (2011). Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome. Mov. Disord. 26, 169-173. doi: 10.1002/mds.23341.
5. Aguilar, M. V., Jiménez-Jiménez, F. J., Molina, J. A., Meseguer, I., Mateos-Vega, C. J., González-Muñoz, M. J., et al. (1998). Cerebrospinal fluid selenium and chromium levels in patients with Parkinson's disease. J. Neural Transm. 105, 1245-1251.
6. Alimonti, A., Bocca, B., Pino, A., Ruggieri, F., Forte, G., and Sancesario, G. (2007). Elemental profile of cerebrospinal fluid in patients with Parkinson's disease. J. Trace Elem. Med. Biol. 21, 234-241. doi: 10.1016/j.jtemb.2007.05.001.
7. Alonso-Navarro, H., Jiménez-Jiménez, F. J., García-Martín, E., and Agúndez, J. A. G. (2014). Genomic and pharmacogenomic biomarkers of Parkinson's disease. Curr. Drug Metab. 15, 129-181. doi: 10.2174/138920021502140327175404.
8. Alonso-Navarro, H., Jiménez-Jiménez, F. J., Pilo de la Fuente, B., and Plaza-Nieto, J. F. (2008). "Mecanismos patogénicos de la enfermedad de Parkinson," in Tratado de los Trastornos del Movimiento, 2nd Edn., Chapter 18, Vol. 1, eds F. J. Jiménez-Jiménez, M. R. Luquin, J. A. Molina, and G. Linazasoro (Barcelona: Viguera Editores, S.L.), 425-485.
9. Alves, G., Brønnick, K., Aarsland, D., Blennow, K., Zetterberg, H., Ballard, C., et al. (2010). CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study. J. Neurol. Neurosurg. Psychiatry 81, 1080-1086. doi: 10.1136/jnnp.2009.199950.
10. Alves, G., Pedersen, K. F., Bloem, B. R., Blennow, K., Zetterberg, H., Borm, G. F., et al. (2013). Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 84, 537-543. doi: 10.1136/jnnp-2012-303808.
11. Andersson, M., Zetterberg, H., Minthon, L., Blennow, K., and Londos, E. (2011). The cognitive profile and CSF biomarkers in dementia with Lewy bodies and Parkinson's disease dementia. Int. J. Geriatr. Psychiatry 26, 100-105 doi: 10.1002/gps.2496.
12. Antkiewicz-Michaluk, L., Krygowska-Wajs, A., Szczudlik, A., Romańska, I., and Vetulani, J. (1997). Increase in salsolinol level in the cerebrospinal fluid of parkinsonian patients is related to dementia: advantage of a new high-performance liquid chromatography methodology. Biol. Psychiatry 42, 514-518. doi: 10.1016/S0006-3223(96)00408-8.
13. Aoyama, K., Matsubara, K., Fujikawa, Y., Nagahiro, Y., Shimizu, K., Umegae, N., et al. (2000). Nitration of manganese superoxide dismutase in cerebrospinal fluids is a marker for peroxynitrite-mediated oxidative stress in neurodegenerative diseases. Ann. Neurol. 47, 524-527. doi: 10.1002/1531-8249(200004)47:43.3.CO;2-X.
14. Aoyama, K., Matsubara, K., Kondo, M., Murakawa, Y., Suno, M., Yamashita, K., et al. (2001). Nicotinamide-N-methyltransferase is higher in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Neurosci. Lett. 298, 78-80. doi: 10.1016/S0304-3940(00)01723-7.
15. Aquilonius, S. M., Nyström, B., Schuberth, J., and Sundwall, A. (1972). Cerebrospinal fluid choline in extrapyramidal disorders. J. Neurol. Neurosurg. Psychiatry 35, 720-725. doi: 10.1136/jnnp.35.5.720.
16. Araki, K., Takino, T., Ida, S., and Kuriyama, K. (1986). Alteration of amino acids in cerebrospinal fluid from patients with Parkinson's disease and spinocerebellar degeneration. Acta Neurol. Scand. 73, 105-110. doi: 10.1111/j.1600-0404.1986.tb03249.x.
17. Asai, H., Hirano, M., Furiya, Y., Udaka, F., Morikawa, M., Kanbayashi, T., et al. (2009). Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson's disease. Clin. Neurol. Neurosurg. 111, 341-344. doi: 10.1016/j.clineuro.2008.11.007.
18. Ascherio, A., LeWitt, P. A., Xu, K., Eberly, S., Watts, A., Matson, W. R., et al. (2009). Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch. Neurol. 66, 1460-1468. doi: 10.1001/archneurol.2009.247.
19. Balducci, C., Pierguidi, L., Persichetti, E., Parnetti, L., Sbaragli, M., Tassi, C., et al. (2007). Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease. Mov. Disord. 22, 1481-1484. doi: 10.1002/mds.21399.
20. Baronti, F., Conant, K. E., Giuffra, M., Davis, T. L., Brughitta, G., Iadarola, M. J., et al. (1991). Opioid peptides in Parkinson's disease: effects of dopamine repletion. Brain Res. 560, 92-96. doi: 10.1016/0006-8993(91)91219-Q.
21. Beal, M. F., Growdon, J. H., Mazurek, M. F., and Martin, J. B. (1986). CSF somatostatin-like immunoreactivity in dementia. Neurology 36, 294-297. doi: 10.1212/WNL.36.2.294.
22. Belmaker, R. H., Ebstein, R. P., Biederman, J., Stern, R., Berman, M., and van Praag, H. M. (1978). The effect of L-dopa and propranolol on human CSF cyclic nucleotides. Psychopharmacology (Berl.) 58, 307-310. doi: 10.1007/BF00427396.
23. Benito-León, J., Alonso-Navarro, H., Pascual-Gómez, J., and Jiménez-Jiménez, F. J. (2008). "Neuroquímica de los trastornos del movimiento," in Tratado de los Trastornos del Movimiento, 2nd Edn., Chapter 7, Vol. 1, eds F. J. Jiménez-Jiménez, M. R. Luquin, J. A. Molina, and G. Linazasoro (Barcelona: Viguera Editores, S.L.), 133-149.
24. Bernheimer, H., Birkmayer, W., and Hornykiewicz, O. (1966). Homovanillic acid in the cerebrospinal fluid: studies in Parkinson's syndrome and other diseases of the CNS. Wien. Klin. Wochenschr. 78, 417-419.
25. Bertler, A., Jeppsson, P. G., Nordgren, L., and Rosengren, E. (1971). Serial determinations of homovanillinic acid in the cerebrospinal fluid of Parkinson patients treated with L-dopa. Acta Neurol. Scand. 47, 393-402. doi: 10.1111/j.1600-0404.1971.tb07494.x.
26. Beyer, M. K., Alves, G., Hwang, K. S., Babakchanian, S., Bronnick, K. S., Chou, Y. Y., et al. (2013). Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease. Mov. Disord. 28, 302-310. doi: 10.1002/mds.25282.
27. Björkhem, I., Lövgren-Sandblom, A., Leoni, V., Meaney, S., Brodin, L., Salveson, L., et al. (2013). Oxysterols and Parkinson's disease: evidence that levels of 24S-hydroxycholesterol in cerebrospinal fluid correlates with the duration of the disease. Neurosci. Lett. 555, 102-105. doi: 10.1016/j.neulet.2013.09.003.
28. Blennow, K., Wallin, A., Agren, H., Spenger, C., Siegfried, J., and Vanmechelen, E. (1995). Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? Mol. Chem. Neuropathol. 26, 231-245. doi: 10.1007/BF02815140.
29. Blum-Degen, D., Müller, T., Kuhn, W., Gerlach, M., Przuntek, H., and Riederer, P. (1995). Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease. Neurosci. Lett. 202, 17-20. doi: 10.1016/0304-3940(95)12192-7.
30. Boll, M. C., Alcaraz-Zubeldia, M., Montes, S., and Rios, C. (2008). Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem. Res. 33, 1717-1723. doi: 10.1007/s11064-008-9610-3.
31. Boll, M. C., Sotelo, J., Otero, E., Alcaraz-Zubeldia, M., and Rios, C. (1999). Reduced ferroxidase activity in the cerebrospinal fluid from patients with Parkinson's disease. Neurosci. Lett. 265, 155-158. doi: 10.1016/S0304-3940(99)00221-9.
32. Bonnet, A. M., Tell, G., Schechter, P. J., Grove, J., Saint-Hilaire, M. H., De Smet, Y., et al. (1987). Cerebrospinal fluid GABA and homocarnosine concentrations in patients with Friedreich's ataxia, Parkinson's disease, and Huntington's chorea. Mov. Disord. 2, 117-123. doi: 10.1002/mds.870020206.
33. Borghi, R., Marchese, R., Negro, A., Marinelli, L., Forloni, G., Zaccheo, D., et al. (2000). Full length alpha-synuclein is present in cerebrospinal fluid from Parkinson's disease and normal subjects. Neurosci. Lett. 287, 65-67. doi: 10.1016/S0304-3940(00)01153-8.
34. Borroni, B., Gardoni, F., Parnetti, L., Magno, L., Malinverno, M., Saggese, E., et al. (2009). Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol. Aging 30, 34-40. doi: 10.1016/j.neurobiolaging.2007.05.009.
35. Borroni, B., Malinverno, M., Gardoni, F., Alberici, A., Parnetti, L., Premi, E., et al. (2008). Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy. Neurology 71, 1796-1803. doi: 10.1212/01.wnl.0000335941.68602.39.
36. Bridoux, A., Moutereau, S., Covali-Noroc, A., Margarit, L., Palfi, S., Nguyen, J. P., et al. (2013). Ventricular orexin-A (hypocretin-1) levels correlate with rapid-eye-movement sleep without atonia in Parkinson's disease. Nat. Sci. Sleep 5, 87-91. doi: 10.2147/NSS.S41245.
37. Buhmann, C., Arlt, S., Kontush, A., Möller-Bertram, T., Sperber, S., Oechsner, M., et al. (2004). Plasma and CSF markers of oxidative stress are increased in Parkinson's disease and influenced by antiparkinsonian medication. Neurobiol. Dis. 15, 160-170. doi: 10.1016/j.nbd.2003.10.003.
38. Burns, R. S., LeWitt, P. A., Ebert, M. H., Pakkenberg, H., and Kopin, I. J. (1985). The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). N. Engl. J. Med. 312, 1418-1421. doi: 10.1056/NEJM198505303122203.
39. Campanella, G., Carrieri, P., Romito, D., and Pasqual-Marsettin, E. (1973). Iron, transferrin, copper and ceruloplasmin of the serum and cerebrospinal fluid in extrapyramidal diseases and primary myopathies. Study in basic conditions and in Parkinsonism after treatment with dopaminergic agents (L-dopa, L-dopa + RO 4-4602, amantadine). Acta Neurol. (Napoli) 28, 1-34.
40. Carvey, P. M., McRae, A., Lint, T. F., Ptak, L. R., Lo, E. S., Goetz, C. G., et al. (1991). The potential use of a dopamine neuron antibody and a striatal-derived neurotrophic factor as diagnostic markers in Parkinson's disease. Neurology 41(5 Suppl. 2), 53-58. discussion: 59-60. doi: 10.1212/WNL.41.5_Suppl_2.53.
41. Casati, C., Agnoli, A., Jori, A., and Dolfini, E. (1973). On the relationship between L-DOPA therapy and CSF monoamine metabolites in Parkinson's disease. Z. Neurol. 204, 149-154.
42. Chase, T. N. (1970). Cerebrospinal fluid monoamine metabolites and peripheral decarboxylase inhibitors in parkinsonism. Neurology 20(Suppl.), 36-40. doi: 10.1212/WNL.20.12_Part_2.36.
43. Cheng, F. C., Kuo, J. S., Chia, L. G., and Dryhurst, G. (1996). Elevated 5-S-cysteinyldopamine/homovanillic acid ratio and reduced homovanillic acid in cerebrospinal fluid: possible markers for and potential insights into the pathoetiology of Parkinson's disease. J Neural Transm 103, 433-446. doi: 10.1007/BF01276419.
44. Chia, L. G., Cheng, F. C., and Kuo, J. S. (1993). Monoamines and their metabolites in plasma and lumbar cerebrospinal fluid of Chinese patients with Parkinson's disease. J. Neurol. Sci. 116, 125-134. doi: 10.1016/0022-510X(93)90316-Q.
45. Christensen, S. E., Dupont, E., Mondrup, K., Olivarius, B. F., and Orskov, H. (1984). Parkinson's disease and benign essential tremor: somatostatin-like immunoreactivity in the cerebrospinal fluid. Adv. Neurol. 40, 325-331.
46. Chu, A. B., Sever, J. L., Madden, D. L., Iivanainen, M., Leon, M., Wallen, W., et al. (1983). Oligoclonal IgG bands in cerebrospinal fluid in various neurological diseases. Ann. Neurol. 13, 434-439. doi: 10.1002/ana.410130410.
47. Compta, Y., Ezquerra, M., Muñoz, E., Tolosa, E., Valldeoriola, F., Rios, J., et al. (2011). High cerebrospinal tau levels are associated with the rs242557 tau gene variant and low cerebrospinal β-amyloid in Parkinson disease. Neurosci. Lett. 487, 169-173. doi: 10.1016/j.neulet.2010.10.015.
48. Compta, Y., Martí, M. J., Ibarretxe-Bilbao, N., Junqué, C., Valldeoriola, F., Muñoz, E., et al. (2009b). Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease. Mov. Disord. 24, 2203-2210. doi: 10.1002/mds.22594.
49. Compta, Y., Pereira, J. B., Ríos, J., Ibarretxe-Bilbao, N., Junqué, C., Bargalló, N., et al. (2013). Combined dementia-risk biomarkers in Parkinson's disease: a prospective longitudinal study. Parkinsonism Relat. Disord. 19, 717-724. doi: 10.1016/j.parkreldis.2013.03.009.
50. Compta, Y., Santamaria, J., Ratti, L., Tolosa, E., Iranzo, A., Muñoz, E., et al. (2009a). Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. Brain 132, 3308-3317. doi: 10.1093/brain/awp263.
51. Constantinescu, R., Andreasson, U., Holmberg, B., and Zetterberg, H. (2013). Serum and cerebrospinal fluid urate levels in synucleinopathies versus tauopathies. Acta Neurol. Scand. 127, e8-e12. doi: 10.1111/ane.12012.
52. Constantinescu, R., Rosengren, L., Johnels, B., Zetterberg, H., and Holmberg, B. (2010). Consecutive analyses of cerebrospinal fluid axonal and glial markers in Parkinson's disease and atypical Parkinsonian disorders. Parkinsonism Relat. Disord. 16, 142-145. doi: 10.1016/j.parkreldis.2009.07.007.
53. Covicković-Sternić, N., Kostić, V. S., Djuricić, B. M., Bumbasirević-Beslać, L., Nikolić, M., and Mrsulja, B. B. (1987). Cyclic nucleotides in cerebrospinal fluid of drug-free Parkinson patients. Eur. Neurol. 27, 24-28. doi: 10.1159/000116124.
54. Cox, B., Danta, G., Schnieden, H., and Yuill, G. M. (1973). Interactions of L-dopa and amantadine in patients with Parkinsonism. J. Neurol. Neurosurg. Psychiatry 36, 354-361. doi: 10.1136/jnnp.36.3.354.
55. Cramer, H., Jost, S., Reuner, C., Milios, E., Geiger, J., and Mundinger, F. (1991). Ventricular fluid neuropeptides in Parkinson's disease. II. Levels of substance P-like immunoreactivity. Neuropeptides 18, 69-73. doi: 10.1016/0143-4179(91)90002-Z.
56. Cramer, H., Ng, L. K., and Chase, T. N. (1973). Adenosine 3',5'-monophosphate in cerebrospinal fluid. Effect of drugs and neurologic disease. Arch. Neurol. 29, 197-199. doi: 10.1001/archneur.1973.00490270079014.
57. Cramer, H., Rissler, K., Rösler, N., Strubel, D., Schaudt, D., and Kuntzmann, F. (1989). Immunoreactive substance P and somatostatin in the cerebrospinal fluid of senile parkinsonian patients. Eur. Neurol. 29, 1-5. doi: 10.1159/000116366.
58. Cramer, H., Warter, J. M., and Renaud, B. (1984). Analysis of neurotransmitter metabolites and adenosine 3',5'-monophosphate in the CSF of patients with extrapyramidal motor disorders. Adv. Neurol. 40, 431-435.
59. Cramer, H., Wolf, A., Rissler, K., Weigel, K., and Ostertag, C. (1985). Ventricular somatostatin-like immunoreactivity in patients with basal ganglia disease. J. Neurol. 232, 219-222. doi: 10.1007/BF00313783.
60. Cunha, L., Gonçalves, A. F., Oliveira, C., Dinis, M., and Amaral, R. (1983). Homovanillic acid in the cerebrospinal fluid of Parkinsonian patients. Can. J. Neurol. Sci. 10, 43-46.
61. Curzon, G., Godwin-Austen, R. B., Tomlinson, E. B., and Kantamaneni, B. D. (1970). The cerebrospinal fluid homovanillic acid concentration in patients with Parkinsonism treated with L-dopa. J. Neurol. Neurosurg. Psychiatry 33, 1-6. doi: 10.1136/jnnp.33.1.1.
62. Davidson, D. L., Yates, C. M., Mawdsley, C., Pullar, I. A., and Wilson, H. (1977). CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders. J. Neurol. Neurosurg. Psychiatry 40, 1136-1141. doi: 10.1136/jnnp.40.12.1136.
63. De Deyn, P. P., Hiramatsu, M., Borggreve, F., Goeman, J., D'Hooge, R., Saerens, J., et al. (1998). Superoxide dismutase activity in cerebrospinal fluid of patients with dementia and some other neurological disorders. Alzheimer Dis. Assoc. Disord. 12, 26-32. doi: 10.1097/00002093-199803000-00004.
64. de Jong, P. J., Lakke, J. P., and Teelken, A. W. (1984). CSF GABA levels in Parkinson's disease. Adv. Neurol. 40, 427-430.
65. de la Monte, S. M., Volicer, L., Hauser, S. L., and Wands, J. R. (1992). Increased levels of neuronal thread protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 32, 733-742. doi: 10.1002/ana.410320606.
66. Dexter, D. T., Carayon, A., Vidailhet, M., Ruberg, M., Agid, F., Agid, Y., et al. (1990). Decreased ferritin levels in brain in Parkinson's disease. J. Neurochem. 55, 16-20. doi: 10.1111/j.1471-4159.1990.tb08814.x.
67. di Michele, F., Longone, P., Romeo, E., Lucchetti, S., Brusa, L., Pierantozzi, M., et al. (2003). Decreased plasma and cerebrospinal fluid content of neuroactive steroids in Parkinson's disease. Neurol. Sci. 24, 172-173. doi: 10.1007/s10072-003-0115-1.
68. Dissing, I. C., Güttler, F., Pakkenberg, H., Lou, H., Gerdes, A. M., Lykkelund, C., et al. (1989). Tetrahydrobiopterin and Parkinson's disease. Acta Neurol. Scand. 79, 493-499. doi: 10.1111/j.1600-0404.1989.tb03820.x.
69. Drouot, X., Moutereau, S., Lefaucheur, J. P., Palfi, S., Covali-Noroc, A., Margarit, L., et al. (2011). Low level of ventricular CSF orexin-A is not associated with objecttive sleepiness in PD. Sleep Med. 12, 936-937. doi: 10.1016/j.sleep.2011.08.002.
70. Drouot, X., Moutereau, S., Nguyen, J. P., Lefaucheur, J. P., Créange, A., Remy, P., et al. (2003). Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology 61, 540-543. doi: 10.1212/01.WNL.0000078194.53210.48.
71. Dupont, E., Christensen, S. E., Hansen, A. P., de Fine Olivarius, B., and Orskov, H. (1982). Low cerebrospinal fluid somatostatin in Parkinson disease: an irreversible abnormality. Neurology 32, 312-314. doi: 10.1212/WNL.32.3.312.
72. Durso, R., Evans, J. E., Josephs, E., Szabo, G. K., Evans, B. A., Handler, J. S., et al. (1997). Central levodopa metabolism in Parkinson's disease after administration of stable isotope-labeled levodopa. Ann. Neurol. 42, 300-304. doi: 10.1002/ana.410420305.
73. Durso, R., Szabo, G., Davoudi, H., and Feldman, R. G. (1989). Magnitude of response to levodopa in Parkinson disease as it relates to peripheral and central measurements of levodopa and associated metabolites. Clin. Neuropharmacol. 12, 384-392. doi: 10.1097/00002826-198910000-00003.
74. Duvoisin, R. C., and Dettbarn, W. D. (1967). Cerebrospinal fluid acetylcholine in man. Neurology 17, 1077-1081. doi: 10.1212/WNL.17.11.1077.
75. Eder, U., Leitner, B., Kirchmair, R., Pohl, P., Jobst, K. A., Smith, A. D., et al. (1998). Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases. J. Neural Transm. 105, 39-51. doi: 10.1007/s007020050036.
76. Eldrup, E., Mogensen, P., Jacobsen, J., Pakkenberg, H., and Christensen, N. J. (1995). CSF and plasma concentrations of free norepinephrine, dopamine, 3,4-dihydroxyphenylacetic acid (DOPAC), 3,4-dihydroxyphenylalanine (DOPA), and epinephrine in Parkinson's disease. Acta Neurol. Scand. 92, 116-121. doi: 10.1111/j.1600-0404.1995.tb01023.x.
77. Engelborghs, S., Marescau, B., and De Deyn, P. P. (2003). Amino acids and biogenic amines in cerebrospinal fluid of patients with Parkinson's disease. Neurochem. Res. 28, 1145-1150. doi: 10.1023/A:1024255208563.
78. Enna, S. J., Stern, L. Z., Wastek, G. J., and Yamamura, H. I. (1977). Cerebrospinal fluid gamma-aminobutyric acid variations in neurological disorders. Arch. Neurol. 34, 683-685. doi: 10.1001/archneur.1977.00500230053008.
79. Ernst, A., Cramer, H., Strubel, D., Kuntzmann, F., and Schoenenberger, G. A. (1987). Comparison of DSIP-(delta sleep-inducing peptide) and P-DSIP-like (phosphorylated) immunoreactivity in cerebrospinal fluid of patients with senile dementia of Alzheimer type, multi-infarct syndrome, communicating hydrocephalus and Parkinson's disease. J. Neurol. 235, 16-21. doi: 10.1007/BF00314191.
80. Espino, A., Ambrosio, S., Bartrons, R., Bendahan, G., and Calopa, M. (1994). Cerebrospinal monoamine metabolites and amino acid content in patients with parkinsonian syndrome and rats lesioned with MPP+. J. Neural Transm. Park. Dis. Dement. Sect. 7, 167-176 doi: 10.1007/BF02253436.
81. Espino, A., Calopa, M., Ambrosio, S., Ortolà, J., Peres, J., and Navarro, M. A. (1995). CSF somatostatin increase in patients with early parkinsonian syndrome. J. Neural Transm. Park. Dis. Dement. Sect. 9, 189-196. doi: 10.1007/BF02259660.
82. Fernández, E., García-Moreno, J. M., Martín de Pablos, A., and Chacón, J. (2013). May the evaluation of nitrosative stress through selective increase of 3-nitrotyrosine proteins other than nitroalbumin and dominant tyrosine-125/136 nitrosylation of serum α-synuclein serve for diagnosis of sporadic Parkinson's disease? Antioxid. Redox Signal. 19, 912-918. doi: 10.1089/ars.2013.5250.
83. Ferrarese, C., Appollonio, I., Frigo, M., Meregalli, S., Piolti, R., Tamma, F., et al. (1990). Cerebrospinal fluid levels of diazepam-binding inhibitor in neurodegenerative disorders with dementia. Neurology 40, 632-635. doi: 10.1212/WNL.40.4.632.
84. Ferrero, P., Benna, P., Costa, P., Tarenzi, L., Baggio, G., Bergamasco, B., et al. (1988). Diazepam binding inhibitor-like immunoreactivity (DBI-LI) in human CSF. Correlations with neurological disorders. J. Neurol. Sci. 87, 327-349. doi: 10.1016/0022-510X(88)90257-2.
85. Finehout, E. J., Franck, Z., and Lee, K. H. (2005). Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis. Markers 21, 93-101. doi: 10.1155/2005/806573.
86. Fiszer, U., Fredrikson, S., and Członkowska, A. (1996). Humoral response to hsp 65 and hsp 70 in cerebrospinal fluid in Parkinson's disease. J. Neurol. Sci. 139, 66-70. doi: 10.1016/0022-510X(96)00002-0.
87. Fiszer, U., Mix, E., Fredrikson, S., Kostulas, V., and Link, H. (1994a). Parkinson's disease and immunological abnormalities: increase of HLA-DR expression on monocytes in cerebrospinal fluid and of CD45RO+ T cells in peripheral blood. Acta Neurol. Scand. 90, 160-166. doi: 10.1111/j.1600-0404.1994.tb02699.x.
88. Fiszer, U., Mix, E., Fredrikson, S., Kostulas, V., Olsson, T., and Link, H. (1994b). gamma delta+ T cells are increased in patients with Parkinson's disease. J. Neurol. Sci. 121, 39-45. doi: 10.1016/0022-510X(94)90154-6.
89. Forte, G., Bocca, B., Senofonte, O., Petrucci, F., Brusa, L., Stanzione, P., et al. (2004). Trace and major elements in whole blood, serum, cerebrospinal fluid and urine of patients with Parkinson's disease. J. Neural Transm. 111, 1031-1040. doi: 10.1007/s00702-004-0124-0.
90. Foulds, P. G., Yokota, O., Thurston, A., Davidson, Y., Ahmed, Z., Holton, J., et al. (2012). Post mortem cerebrospinal fluid α-synuclein levels are raised in multiple system atrophy and distinguish this from the other α-synucleinopathies, Parkinson's disease and Dementia with Lewy bodies. Neurobiol. Dis. 45, 188-195. doi: 10.1016/j.nbd.2011.08.003.
91. Friedman, A. (1985). [Drug-induced dyskinesia during the treatment of Parkinson disease-biochemical studies]. Neurol. Neurochir. Pol. 19, 401-403.
92. Fronczek, R., Overeem, S., Lee, S. Y., Hegeman, I. M., van Pelt, J., van Duinen, S. G., et al. (2007). Hypocretin (orexin) loss in Parkinson's disease. Brain 130, 1577-1585. doi: 10.1093/brain/awm090.
93. Fujishiro, K., Hagihara, M., Takahashi, A., and Nagatsu, T. (1990). Concentrations of neopterin and biopterin in the cerebrospinal fluid of patients with Parkinson's disease. Biochem. Med. Metab. Biol. 44, 97-100. doi: 10.1016/0885-4505(90)90049-7.
94. Fukuda, H., Nakamura, S., Hara, K., Udaka, F., and Kameyama, M. (1989). [Study on the concentration of 5-hydroxyindoleacetic acid (5-HIAA) in the lumbar cerebrospinal fluid (CSF) in neurological diseases]. Rinsho Shinkeigaku 29, 1192-1194.
95. Furukawa, Y., Kondo, T., Nishi, K., Yokochi, F., and Narabayashi, H. (1991). Total biopterin levels in the ventricular CSF of patients with Parkinson's disease: a comparison between akineto-rigid and tremor types. J. Neurol. Sci. 103, 232-237. doi: 10.1016/0022-510X(91)90169-8.
96. Furukawa, Y., Nishi, K., Kondo, T., Mizuno, Y., and Narabayashi, H. (1992). Juvenile parkinsonism: ventricular CSF biopterin levels and clinical features. J. Neurol. Sci. 108, 207-213. doi: 10.1016/0022-510X(92)90053-N.
97. Galard, R., Catalán, R., Montalbán, J., Molins, A., Miquel, F., and Castellanos, J. M. (1992). Neurokinin concentrations in cerebrospinal fluid. A preliminary study in Parkinson's disease. Eur. J. Clin. Chem. Clin. Biochem. 30, 281-284.
98. Gazzaniga, G. C., Ferraro, B., Camerlingo, M., Casto, L., Viscardi, M., and Mamoli, A. (1992). A case control study of CSF copper, iron and manganese in Parkinson disease. Ital. J. Neurol. Sci. 13, 239-243. doi: 10.1007/BF02224396.
99. Gibson, C. J., Logue, M., and Growdon, J. H. (1985). CSF monoamine metabolite levels in Alzheimer's and Parkinson's disease. Arch. Neurol. 42, 489-492. doi: 10.1001/archneur.1985.04060050091016.
100. Gjessing, L. R., Gjesdahl, P., Dietrichson, P., and Presthus, J. (1974). Free amino acids in the cerebrospinal fluid in old age and in Parkinson's disease. Eur. Neurol. 12, 33-37. doi: 10.1159/000114602.
101. Godwin-Austen, R. B., Kantamaneni, B. D., and Curzon, G. (1971). Comparison of benefit from L-dopa in Parkinsonism with increase of amine metabolites in the CSF. J. Neurol. Neurosurg. Psychiatry 34, 219-223. doi: 10.1136/jnnp.34.3.219.
102. Goldstein, D. S., Holmes, C., Bentho, O., Sato, T., Moak, J., Sharabi, Y., et al. (2008). Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat. Disord. 14, 600-607. doi: 10.1016/j.parkreldis.2008.01.010.
103. González-Quevedo, A., García, J. C., Fernández, R., and Fernández Cartaya, L. (1993). Monoamine metabolites in normal human cerebrospinal fluid and in degenerative diseases of the central nervous system. Bol. Estud. Med. Biol. 41, 13-19.
104. Gottfries, C. G., Gottfries, I., and Roos, B. E. (1969). Homovanillic acid and 5-hydroxyindoleacetic acid in the cerebrospinal fluid of patients with senile dementia, presenile dementia and parkinsonism. J. Neurochem. 16, 1341-1345. doi: 10.1111/j.1471-4159.1969.tb05984.x.
105. Granerus, A. K., Magnusson, T., Roos, B. E., and Svanborg, A. (1974). Relationship of age and mood to monoamine metabolites in cerebrospinal fluid in parkinsonism. Eur. J. Clin. Pharmacol. 7, 105-109. doi: 10.1007/BF00561323.
106. Gründig, E., and Gerstenbrand, F. (1980). [Comparison between the effects of L-dopa, prodipine and amantadine on the serum and CSF amino acid levels in Parkinson's disease (author's transl)]. Wien. Klin. Wochenschr. 92, 868-871.
107. Guldberg, H. C., Turner, J. W., Hanieh, A., Ashcroft, G. W., Crawford, T. B., Perry, W. L., et al. (1967). On the occurrence of homovanillic acid and 5-hydroxyindol-3-ylacetic acid in the ventricular C.S.F. of patients suffering from parkinsonism. Confin. Neurol. 29, 73-77. doi: 10.1159/000103680.
108. Gumpert, J., Sharpe, D., and Curzon, G. (1973). Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa. J. Neurol. Sci. 19, 1-12. doi: 10.1016/0022-510X(73)90050-6.
109. Guo, J., Sun, Z., Xiao, S., Liu, D., Jin, G., Wang, E., et al. (2009). Proteomic analysis of the cerebrospinal fluid of Parkinson's disease patients. Cell Res. 19, 1401-1403. doi: 10.1038/cr.2009.131.
110. Hagihara, M., and Nagatsu, T. (1987). Post-proline cleaving enzyme in human cerebrospinal fluid from control patients and parkinsonian patients. Biochem. Med. Metab. Biol. 38, 387-391. doi: 10.1016/0885-4505(87)90103-4.
111. Hagihara, M., Mihara, R., Togari, A., and Nagatsu, T. (1987). Dipeptidyl-aminopeptidase II in human cerebrospinal fluid: changes in patients with Parkinson's disease. Biochem. Med. Metab. Biol. 37, 360-365. doi: 10.1016/0885-4505(87)90049-1.
112. Hall, S., Öhrfelt, A., Constantinescu, R., Andreasson, U., Surova, Y., Bostrom, F., et al. (2012). Accuracy of a panel of 5 cerebrospinal fluid biomarkers in the differential diagnosis of patients with dementia and/or parkinsonian disorders. Arch. Neurol. 69, 1445-1452. doi: 10.1001/archneurol.2012.1654.
113. Hartikainen, P., Reinikainen, K. J., Soininen, H., Sirviö, J., Soikkeli, R., and Riekkinen, P. J. (1992). Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls. J. Neural Transm. Park. Dis. Dement. Sect. 4, 53-68. doi: 10.1007/BF02257622.
114. Herbert, M. K., Eeftens, J. M., Aerts, M. B., Esselink, R. A., Bloem, B. R., Kuiperij, H. B., et al. (2014). CSF levels of DJ-1 and tau distinguish MSA patients from PD patients and controls. Parkinsonism Relat. Disord. 20, 112-115. doi: 10.1016/j.parkreldis.2013.09.003.
115. Holmberg, B., Johnels, B., Blennow, K., and Rosengren, L. (2003). Cerebrospinal fluid Abeta42 is reduced in multiple system atrophy but normal in Parkinson's disease and progressive supranuclear palsy. Mov. Disord. 18, 186-190. doi: 10.1002/mds.10321.
116. Holmberg, B., Rosengren, L., Karlsson, J. E., and Johnels, B. (1998). Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple-system atrophy compared with Parkinson's disease. Mov. Disord. 13, 70-77. doi: 10.1002/mds.870130116.
117. Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., et al. (2010). DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain 133, 713-726. doi: 10.1093/brain/awq008.
118. Hozumi, I., Hasegawa, T., Honda, A., Ozawa, K., Hayashi, Y., Hashimoto, K., et al. (2011). Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. J. Neurol. Sci. 303, 95-99. doi: 10.1016/j.jns.2011.01.003.
119. Hurst, J. H., LeWitt, P. A., Burns, R. S., Foster, N. L., and Lovenberg, W. (1985). CSF dopamine-beta-hydroxylase activity in Parkinson's disease. Neurology 35, 565-568. doi: 10.1212/WNL.35.4.565.
120. Iacono, R. P., Kuniyoshi, S. M., Ahlman, J. R., Zimmerman, G. J., Maeda, G., and Pearlstein, R. D. (1997). Concentrations of indoleamine metabolic intermediates in the ventricular cerebrospinal fluid of advanced Parkinson's patients with severe postural instability and gait disorders. J. Neural Transm. 104, 451-459. doi: 10.1007/BF01277663.
121. Ikeda, M., Sato, I., Yuasa, T., Miyatake, T., and Murota, S. (1995). Nitrite, nitrate and cGMP in the cerebrospinal fluid in degenerative neurologic diseases. J. Neural Transm. Gen. Sect. 100, 263-267. doi: 10.1007/BF01276464.
122. Ilic, T. V., Jovanovic, M., Jovicic, A., and Tomovic, M. (1999). Oxidative stress indicators are elevated in de novo Parkinson's disease patients. Funct. Neurol. 14, 141-147.
123. Ilić, T., Jovanović, M., Jovicić, A., and Tomović, M. (1998). Oxidative stress and Parkinson's disease. Vojnosanit. Pregl. 55, 463-468.
124. Irkeç, C., Ercan, S., and Irkeç, M. (1989). Leukotrienes and neurological diseases. Mikrobiyol. Bul. 23, 342-347.
125. Ishibashi, K., Kanemaru, K., Saito, Y., Murayama, S., Oda, K., Ishiwata, K., et al. (2010). Cerebrospinal fluid metabolite and nigrostriatal dopaminergic function in Parkinson's disease. Acta Neurol. Scand. 122, 46-51. doi: 10.1111/j.1600-0404.2009.01255.x.
126. Isobe, C., Abe, T., and Terayama, Y. (2010a). L-Dopa therapy increases homocysteine concentration in cerebrospinal fluid from patients with Parkinson's disease. J. Clin. Neurosci. 17, 717-721. doi: 10.1016/j.jocn.2009.09.034.
127. Isobe, C., Abe, T., and Terayama, Y. (2010b). Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2'-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. Neurosci. Lett. 469, 159-163. doi: 10.1016/j.neulet.2009.11.065.
128. Isobe, C., Murata, T., Sato, C., and Terayama, Y. (2005). Increase of total homocysteine concentration in cerebrospinal fluid in patients with Alzheimer's disease and Parkinson's disease. Life Sci. 77, 1836-1843. doi: 10.1016/j.lfs.2005.02.014.
129. Isobe, C., Murata, T., Sato, C., and Terayama, Y. (2007). Increase of oxidized/total coenzyme Q-10 ratio in cerebrospinal fluid in patients with Parkinson's disease. J. Clin. Neurosci. 14, 340-343. doi: 10.1016/j.jocn.2005.12.023.
130. Jakowec, M. W., Petzinger, G. M., Sastry, S., Donaldson, D. M., McCormack, A., and Langston, J. W. (1998). The native form of alpha-synuclein is not found in the cerebrospinal fluid of patients with Parkinson's disease or normal controls. Neurosci. Lett. 253, 13-16. doi: 10.1016/S0304-3940(98)00599-0.
131. Jansen Steur, E., Vermes, I., and de Vos, R. A. (1998). Cerebrospinal-fluid tau protein and aspartate aminotransferase in Parkinson's disease. Lancet 351, 1105-1106. doi: 10.1016/S0140-6736(05)79387-9.
132. Jellinger, K. A. (2012). CSF biomarkers in different phenotypes of Parkinson disease. J. Neural Transm. 119, 455-456. doi: 10.1007/s00702-011-0736-0.
133. Jesse, S., Lehnert, S., Jahn, O., Parnetti, L., Soininen, H., Herukka, S. K., et al. (2012). Differential sialylation of serpin A1 in the early diagnosis of Parkinson's disease dementia. PLoS ONE 7:e48783. doi: 10.1371/journal.pone.0048783.
134. Jiménez-Jiménez, F. J., Molina, J. A., Aguilar, M. V., Meseguer, I., Mateos-Vega, C. J., González-Muñoz, M. J., et al. (1998). Cerebrospinal fluid levels of transition metals in patients with Parkinson's disease. J. Neural Transm. 105, 497-505.
135. Jiménez-Jiménez, F. J., Molina, J. A., Hernánz, A., Fernández-Vivancos, E., de Bustos, F., Barcenilla, B., et al. (1999). Cerebrospinal fluid levels of thiamine in patients with Parkinson's disease. Neurosci. Lett. 271, 33-36. doi: 10.1016/S0304-3940(99)00515-7.
136. Jiménez-Jiménez, F. J., Molina, J. A., Vargas, C., Gómez, P., De Bustos, F., Zurdo, M., et al. (2000). Normal cerebrospinal fluid levels of insulin in patients with Parkinson's disease. J. Neural Transm. 107, 445-449. doi: 10.1007/s007020050015.
137. Jiménez-Jiménez, F. J., Molina, J. A., Vargas, C., Gómez, P., Navarro, J. A., Benito-León, J., et al. (1996). Neurotransmitter amino acids in cerebrospinal fluid of patients with Parkinson's disease. J. Neurol. Sci. 141, 39-44. doi: 10.1016/0022-510X(96)00115-3.
138. Jiménez-Jiménez, F. J., Rubio, J. C., Molina, J. A., Martín, M. A., Campos, Y., Benito-León, J., et al. (1997). Cerebrospinal fluid carnitine levels in patients with Parkinson's disease. J. Neurol. Sci. 145, 183-185. doi: 10.1016/S0022-510X(96)00259-6.
139. Jiménez-Jiménez, F. J., Trejo Gabriel y Galán, J. M., and Fuentes, J. A. (1994). Neuropéptidos y enfermedad de Parkinson. Rev. Neurol. 22, 5-11.
140. Johansson, B., and Roos, B. E. (1967). 5-hydroxyindoleacetic and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's syndrome. Life Sci. 6, 1449-1454. doi: 10.1016/0024-3205(67)90193-2.
141. Johansson, B., and Roos, B. E. (1971). 5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L dopa. Eur. J. Clin. Pharmacol. 3, 232-235. doi: 10.1007/BF00565012.
142. Jolkkonen, J. T., Soininen, H. S., and Riekkinen, P. J. (1987). beta-Endorphin-like immunoreactivity in cerebrospinal fluid of patients with Alzheimer's disease and Parkinson's disease. J. Neurol. Sci. 77, 153-159. doi: 10.1016/0022-510X(87)90118-3.
143. Jolkkonen, J., Soininen, H., Halonen, T., Ylinen, A., Laulumaa, V., Laakso, M., et al. (1986). Somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with Parkinson's disease and its relation to dementia. J. Neurol. Neurosurg. Psychiatry 49, 1374-1377. doi: 10.1136/jnnp.49.12.1374.
144. Jost, S., Reuner, C., Mohadjer, M., Mundinger, F., and Cramer, H. (1990). Ventricular fluid neuropeptides in Parkinson's disease. I. Levels and distribution of somatostatin-like immunoreactivity. Neuropeptides 15, 219-225. doi: 10.1016/0143-4179(90)90016-R.
145. Kanemaru, K., Mitani, K., and Yamanouchi, H. (1998). Cerebrospinal fluid homovanillic acid levels are not reduced in early corticobasal degeneration. Neurosci. Lett. 245, 121-122. doi: 10.1016/S0304-3940(98)00181-5.
146. Kang, J. H., Irwin, D. J., Chen-Plotkin, A. S., Siderowf, A., Caspell, C., Coffey, C. S., et al. (2013). Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. JAMA Neurol. 70, 1277-1287. doi: 10.1001/jamaneurol.2013.3861.
147. Kikuchi, A., Takeda, A., Onodera, H., Kimpara, T., Hisanaga, K., Sato, N., et al. (2002). Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol. Dis. 9, 244-248. doi: 10.1006/nbdi.2002.0466.
148. Konings, C. H., Kuiper, M. A., Bergmans, P. L., Grijpma, A. M., van Kamp, G. J., and Wolters, E. C. (1994). Increased angiotensin-converting enzyme activity in cerebrospinal fluid of treated patients with Parkinson's disease. Clin. Chim. Acta 231, 101-106. doi: 10.1016/0009-8981(94)90259-3.
149. Konings, C. H., Kuiper, M. A., Mulder, C., Calliauw, J., and Wolters, E. C. (1995). CSF acetylcholinesterase in Parkinson disease: decreased enzyme activity and immunoreactivity in demented patients. Clin. Chim. Acta 235, 101-105. doi: 10.1016/0009-8981(95)06004-9.
150. Konings, C. H., Kuiper, M. A., Teerlink, T., Mulder, C., Scheltens, P., and Wolters, E. C. (1999). Normal cerebrospinal fluid glutathione concentrations in Parkinson's disease, Alzheimer's disease and multiple system atrophy. J. Neurol. Sci. 168, 112-115. doi: 10.1016/S0022-510X(99)00167-7.
151. Koshiba, S., Tokuoka, H., Yokoyama, T., Horiuchi, E., Ichinose, H., and Hasegawa, K. (2011). Biopterin levels in the cerebrospinal fluid of patients with PARK8 (I2020T). J. Neural Transm. 118, 899-903 doi: 10.1007/s00702-011-0587-8.
152. Kostić, V. S., Djuricić, B. M., Covicković-Sternić, N., Bumbasirević, L., Nikolić, M., and Mrsulja, B. B. (1987). Depression and Parkinson's disease: possible role of serotonergic mechanisms. J. Neurol. 234, 94-96. doi: 10.1007/BF00314109.
153. Kotake, Y., Tasaki, Y., Makino, Y., Ohta, S., and Hirobe, M. (1995). 1-Benzyl-1,2,3,4-tetrahydroisoquinoline as a parkinsonism-inducing agent: a novel endogenous amine in mouse brain and parkinsonian CSF. J. Neurochem. 65, 2633-2638. doi: 10.1046/j.1471-4159.1995.65062633.x.
154. Krygowska-Wajs, A., Szczudlik, A., Antkiewicz-Michaluk, L., Romańska, I., and Vetulani, J. (1997). Salsolinol, 3-O-methyl-dopa and homovanillic acid in the cerebrospinal fluid of Parkinson patients. Neurol. Neurochir. Pol. 31, 875-885.
155. Kuhn, W., Müller, T., Gerlach, M., Sofic, E., Fuchs, G., Heye, N., et al. (1996a). Depression in Parkinson's disease: biogenic amines in CSF of "de novo " patients. J. Neural Transm. 103, 1441-1445. doi: 10.1007/BF01271258.
156. Kuhn, W., Müller, T., Grosse, H., and Rommelspacher, H. (1996b). Elevated levels of harman and norharman in cerebrospinal fluid of parkinsonian patients. J. Neural Transm. 103, 1435-1440. doi: 10.1007/BF01271257.
157. Kuiper, M. A., Mulder, C., van Kamp, G. J., Scheltens, P., and Wolters, E. C. (1994a). Cerebrospinal fluid ferritin levels of patients with Parkinson's disease, Alzheimer's disease, and multiple system atrophy. J. Neural Transm. Park. Dis. Dement. Sect. 7, 109-114. doi: 10.1007/BF02260965.
158. Kuiper, M. A., Teerlink, T., Visser, J. J., Bergmans, P. L., Scheltens, P., and Wolters, E. C. (2000). L-glutamate, L-arginine and L-citrulline levels in cerebrospinal fluid of Parkinson's disease, multiple system atrophy, and Alzheimer's disease patients. J. Neural Transm. 107, 183-189. doi: 10.1007/s007020050016.
159. Kuiper, M. A., Visser, J. J., Bergmans, P. L., Scheltens, P., and Wolters, E. C. (1994b). Decreased cerebrospinal fluid nitrate levels in Parkinson's disease, Alzheimer's disease and multiple system atrophy patients. J. Neurol. Sci. 121, 46-49. doi: 10.1016/0022-510X(94)90155-4.
160. Kuroda, H. (1983). Gamma-aminobutyric acid (GABA) in cerebrospinal fluid. Acta Med. Okayama 37, 167-177.
161. Kuroda, H., Ogawa, N., Yamawaki, Y., Nukina, I., Ofuji, T., Yamamoto, M., et al. (1982). Cerebrospinal fluid GABA levels in various neurological and psychiatric diseases. J. Neurol. Neurosurg. Psychiatry 45, 257-260. doi: 10.1136/jnnp.45.3.257.
162. Lakke, J. P., and Teelken, A. W. (1976). Amino acid abnormalities in cerebrospinal fluid of patients with parkinsonism and extrapyramidal disorders. Neurology 26, 489-493. doi: 10.1212/WNL.26.5.489.
163. Lakke, J. P., Teelken, A. W., vd Voet, H., and Wolthers, B. G. (1987). Amino acid abnormalities in cerebrospinal fluid and blood serum of patients with Parkinson's disease, other heredodegenerative disorders and head injuries. Adv. Neurol. 45, 243-247.
164. Lee, P. H., Lee, G., and Paik, M. J. (2008). Polyunsaturated fatty acid levels in the cerebrospinal fluid of patients with Parkinson's disease and multiple system atrophy. Mov. Disord. 23, 309-310. doi: 10.1002/mds.21846.
165. LeWitt, P. A., Li, J., Lu, M., Beach, T. G., Adler, C. H., and Guo, L. (2013). Arizona Parkinson's Disease Consortium. 3-hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis. Mov. Disord. 28, 1653-1660. doi: 10.1002/mds.25555.
166. LeWitt, P., Schultz, L., Auinger, P., and Lu, M. (2011). Parkinson Study Group DATATOP Investigators. CSF xanthine, homovanillic acid, and their ratio as biomarkers of Parkinson's disease. Brain Res. 1408, 88-97. doi: 10.1016/j.brainres.2011.06.057.
167. Lipman, I. J., and Papadopoulos, N. M. (1973). Cerebrospinal fluid N-acetyl neuraminic acid in Parkinson's disease, before and after L-dopa therapy. Dis. Nerv. Syst. 34, 59-62.
168. Liu, D. K. (1989). The concentration of homovanillic acid and leucine-enkephalin in the lumbar CSF of patients with Parkinson's disease before and after madopar treatment. Zhonghua Shen Jing Jing Shen Ke Za Zhi 22, 95-98; 126-127.
169. Liu, H., Iacono, R. P., Schoonenberg, T., Kuniyoshi, S., and Buchholz, J. (1999). A comparative study on neurochemistry of cerebrospinal fluid in advanced Parkinson's disease. Neurobiol. Dis. 6, 35-42. doi: 10.1006/nbdi.1998.0222.
170. Loeffler, D. A., DeMaggio, A. J., Juneau, P. L., Brickman, C. M., Mashour, G. A., Finkelman, J. H., et al. (1994). Ceruloplasmin is increased in cerebrospinal fluid in Alzheimer's disease but not Parkinson's disease. Alzheimer Dis. Assoc. Disord. 8, 190-197. doi: 10.1097/00002093-199408030-00005.
171. Lotstra, F., Verbanck, P. M., Gilles, C., Mendlewicz, J., and Vanderhaeghen, J. J. (1985). Reduced cholecystokinin levels in cerebrospinal fluid of parkinsonian and schizophrenic patients. Ann. N.Y. Acad. Sci. 448, 507-517. doi: 10.1111/j.1749-6632.1985.tb29944.x.
172. Lovenberg, W., Levine, R. A., Robinson, D. S., Ebert, M., Williams, A. C., and Calne, D. B. (1979). Hydroxylase cofactor activity in cerebrospinal fluid of normal subjects and patients with Parkinson's disease. Science 204, 624-626. doi: 10.1126/science.432666.
173. Lunardi, G., Galati, S., Tropepi, D., Moschella, V., Brusa, L., Pierantozzi, M., et al. (2009). Correlation between changes in CSF dopamine turnover and development of dyskinesia in Parkinson's disease. Parkinsonism Relat. Disord. 15, 383-389. doi: 10.1016/j.parkreldis.2008.10.001.
174. Maarouf, C. L., Beach, T. G., Adler, C. H., Shill, H. A., Sabbagh, M. N., Wu, T., et al. (2012). Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson's disease subjects. Neurol Res. 34, 669-676. doi: 10.1179/1743132812Y.0000000063.
175. Maetzler, W., Berg, D., Schalamberidze, N., Melms, A., Schott, K., Mueller, J. C., et al. (2007). Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model. Neurobiol. Dis. 25, 473-482 doi: 10.1016/j.nbd.2006.10.020.
176. Maetzler, W., Tian, Y., Baur, S. M., Gauger, T., Odoj, B., Schmid, B., et al. (2012). Serum and cerebrospinal fluid levels of transthyretin in Lewy body disorders with and without dementia. PLoS ONE 7:e48042. doi: 10.1371/journal.pone.0048042.
177. Mally, J., Szalai, G., and Stone, T. W. (1997). Changes in the concentration of amino acids in serum and cerebrospinal fluid of patients with Parkinson's disease. J. Neurol. Sci. 151, 159-162. doi: 10.1016/S0022-510X(97)00119-6.
178. Mann, J. J., Stanley, M., Kaplan, R. D., Sweeney, J., and Neophytides, A. (1983). Central catecholamine metabolismin vivo and the cognitive and motor deficits in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 46, 905-910. doi: 10.1136/jnnp.46.10.905.
179. Manyam, B. V. (1982). Low CSF gamma-aminobutyric acid levels in Parkinson's Disease. Effect of levodopa and carbidopa. Arch. Neurol. 39, 391-392 doi: 10.1001/archneur.1982.00510190009002.
180. Manyam, B. V., and Tremblay, R. D. (1984). Free and conjugated GABA in human cerebrospinal fluid: effect of degenerative neurologic diseases and isoniazid. Brain Res. 307, 217-223. doi: 10.1016/0006-8993(84)90475-X.
181. Manyam, B. V., Ferraro, T. N., and Hare, T. A. (1988). Cerebrospinal fluid amino compounds in Parkinson's disease. Alterations due to carbidopa/levodopa. Arch. Neurol. 45, 48-50. doi: 10.1001/archneur.1988.00520250054021.
182. Manyam, B. V., Giacobini, E., and Colliver, J. A. (1990). Cerebrospinal fluid choline levels are decreased in Parkinson's disease. Ann. Neurol. 27, 683-685. doi: 10.1002/ana.410270616.
183. Manyam, N. V., Katz, L., Hare, T. A., Gerber, J. C. 3rd., and Grossman, M. H. (1980). Levels of gamma-aminobutyric acid in cerebrospinal fluid in various neurologic disorders. Arch. Neurol. 37, 352-355. doi: 10.1001/archneur.1980.00500550054006.
184. Mariani, S., Ventriglia, M., Simonelli, I., Donno, S., Bucossi, S., Vernieri, F., et al. (2013). Fe and Cu do not differ in Parkinson's disease: a replication study plus meta-analysis. Neurobiol. Aging 34, 632-633. doi: 10.1016/j.neurobiolaging.2012.05.015.
185. Martignoni, E., Blandini, F., Petraglia, F., Pacchetti, C., Bono, G., and Nappi, G. (1992). Cerebrospinal fluid norepinephrine, 3-methoxy-4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. J. Neural Transm. Park. Dis. Dement. Sect. 4, 191-205. doi: 10.1007/BF02260903.
186. Marttila, R. J., Lorentz, H., and Rinne, U. K. (1988). Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J. Neurol. Sci. 86, 321-331. doi: 10.1016/0022-510X(88)90108-6.
187. Maruyama, W., Abe, T., Tohgi, H., Dostert, P., and Naoi, M. (1996). A dopaminergic neurotoxin, (R)-N-methylsalsolinol, increases in Parkinsonian cerebrospinal fluid. Ann. Neurol. 40, 119-122. doi: 10.1002/ana.410400120.
188. Maruyama, W., Abe, T., Tohgi, H., and Naoi, M. (1999). An endogenous MPTP-like dopaminergic neurotoxin, N-methyl(R)salsolinol, in the cerebrospinal fluid decreases with progression of Parkinson's disease. Neurosci. Lett. 262, 13-16. doi: 10.1016/S0304-3940(99)00003-8.
189. Maruyama, W., Naoi, M., and Narabayashi, H. (1994). The effect of droxidopa on the monoamine metabolsim in the human brain. Rinsho Shinkeigaku 34, 985-990.
190. Mashayekhi, F., Mirzajani, E., Naji, M., and Azari, M. (2010). Expression of insulin-like growth factor-1 and insulin-like growth factor binding proteins in the serum and cerebrospinal fluid of patients with Parkinson's disease. J. Clin. Neurosci. 17, 623-627. doi: 10.1016/j.jocn.2009.08.013.
191. Mashige, F., Takai, N., Matsushima, Y., Ito, A., Takano, M., Tsuchiya, E., et al. (1994). Simultaneous determination of catecholamines, serotonin, and their precursors and metabolites in body fluid by an HPLC system with multi-electrode electrochemical detector. Rinsho Byori 42, 591-599.
192. Masson, H., Popescu, I., Strubel, D., Cramer, H., and Kuntzmann, F. (1990). Somatostatin-like immunoreactivity in the cerebrospinal fluid of aged patients with Parkinson's disease. The effect of dopatherapy. J. Am. Geriatr. Soc. 38, 19-24.
193. Matsubara, K., Kobayashi, S., Kobayashi, Y., Yamashita, K., Koide, H., Hatta, M., et al. (1995). beta-Carbolinium cations, endogenous MPP+ analogs, in the lumbar cerebrospinal fluid of patients with Parkinson's disease. Neurology 45, 2240-2245. doi: 10.1212/WNL.45.12.2240.
194. Matsui, H., Kato, T., Yamamoto, C., Fujita, K., and Nagatsu, T. (1981). Highly sensitive assay for dopamine-beta-hydroxylase activity in human cerebrospinal fluid by high performance liquid chromatography-electrochemical detection: properties of the enzyme. J. Neurochem. 37, 289-296. doi: 10.1111/j.1471-4159.1981.tb00454.x.
195. Mayeux, R., Stern, Y., Cote, L., and Williams, J. B. (1984). Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 34, 642-646. doi: 10.1212/WNL.34.5.642.
196. Mayeux, R., Stern, Y., Sano, M., Cote, L., and Williams, J. B. (1987). Clinical and biochemical correlates of bradyphrenia in Parkinson's disease. Neurology 37, 1130-1134. doi: 10.1212/WNL.37.7.1130.
197. Mayeux, R., Stern, Y., Sano, M., Williams, J. B., and Cote, L. J. (1988). The relationship of serotonin to depression in Parkinson's disease. Mov. Disord. 3, 237-244. doi: 10.1002/mds.870030308.
198. Mayeux, R., Stern, Y., Williams, J. B., Cote, L., Frantz, A., and Dyrenfurth, I. (1986). Clinical and biochemical features of depression in Parkinson's disease. Am. J. Psychiatry 143, 756-759.
199. McLellan, D. L., Chalmers, R. J., and Johnson, R. H. (1975). Clinical and pharmacological evaluation of the effects of piribedil in patients with parkinsonism. Acta Neurol. Scand. 51, 74-82. doi: 10.1111/j.1600-0404.1975.tb01360.x.
200. Mena, M. A., Aguado, E. G., and de Yebenes, J. G. (1984). Monoamine metabolites in human cerebrospinal fluid. HPLC/ED method. Acta Neurol. Scand. 69, 218-225. doi: 10.1111/j.1600-0404.1984.tb07804.x.
201. Meyne, F., Gloeckner, S. F., Ciesielczyk, B., Heinemann, U., Krasnianski, A., Meissner, B., et al. (2009). Total prion protein levels in the cerebrospinal fluid are reduced in patients with various neurological disorders. J. Alzheimers Dis. 17, 863-873. doi: 10.3233/JAD-2009-1110.
202. Mogi, M., and Nagatsu, T. (1999). Neurotrophins and cytokines in Parkinson's disease. Adv. Neurol. 80, 135-139.
203. Mogi, M., Harada, M., Kojima, K., Adachi, T., Narabayashi, H., Fujita, K., et al. (1989). Beta 2-microglobulin decrease in cerebrospinal fluid from Parkinsonian patients. Neurosci. Lett. 104, 241-246. doi: 10.1016/0304-3940(89)90361-3.
204. Mogi, M., Harada, M., Kondo, T., Mizuno, Y., Narabayashi, H., Riederer, P., et al. (1996b). bcl-2 protein is increased in the brain from parkinsonian patients. Neurosci. Lett. 215, 137-139. doi: 10.1016/0304-3940(96)12961-X.
205. Mogi, M., Harada, M., Kondo, T., Narabayashi, H., Riederer, P., and Nagatsu, T. (1995). Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Neurosci. Lett. 193, 129-132. doi: 10.1016/0304-3940(95)11686-Q.
206. Mogi, M., Harada, M., Narabayashi, H., Inagaki, H., Minami, M., and Nagatsu, T. (1996a). Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci. Lett. 211, 13-16. doi: 10.1016/0304-3940(96)12706-3.
207. Mogi, M., Harada, M., Riederer, P., Narabayashi, H., Fujita, K., and Nagatsu, T. (1994). Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci. Lett. 165, 208-210. doi: 10.1016/0304-3940(94)90746-3.
208. Molina, J. A., Benito-León, J., Jiménez-Jiménez, F. J., Ortí-Pareja, M., Berbel, A., Tallón-Barranco, A., et al. (1997c). Tau protein concentrations in cerebrospinal fluid of non-demented Parkinson's disease patients. Neurosci. Lett. 238, 139-141. doi: 10.1016/S0304-3940(97)00858-6.
209. Molina, J. A., de Bustos, F., Jiménez-Jiménez, F. J., Benito-León, J., Ortí-Pareja, M., Gasalla, T., et al. (1997b). Cerebrospinal fluid levels of alpha-tocopherol (vitamin E) in Parkinson's disease. J. Neural Transm. 104, 1287-1293. doi: 10.1007/BF01294729.
210. Molina, J. A., Jiménez-Jiménez, F. J., Gomez, P., Vargas, C., Navarro, J. A., Ortí-Pareja, M., et al. (1997a). Decreased cerebrospinal fluid levels of neutral and basic amino acids in patients with Parkinson's disease. J. Neurol. Sci. 150, 123-127. doi: 10.1016/S0022-510X(97)00069-5.
211. Molina, J. A., Jiménez-Jiménez, F. J., Navarro, J. A., Vargas, C., Gómez, P., Benito-León, J., et al. (1996). Cerebrospinal fluid nitrate levels in patients with Parkinson's disease. Acta Neurol. Scand. 93, 123-126. doi: 10.1111/j.1600-0404.1996.tb00186.x.
212. Molina, J. A., Jiménez-Jiménez, F. J., Ortí-Pareja, M., and Navarro, J. A. (1998). The role of nitric oxide in neurodegeneration: potential for pharmacological intervention. Drugs Aging 12, 251-259. doi: 10.2165/00002512-199812040-00001.
213. Mollenhauer, B., Locascio, J. J., Schulz-Schaeffer, W., Sixel-Döring, F., Trenkwalder, C., and Schlossmacher, M. G. (2011). α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study. Lancet Neurol. 10, 230-240. doi: 10.1016/S1474-4422(11)70014-X.
214. Mollenhauer, B., Trautmann, E., Taylor, P., Manninger, P., Sixel-Döring, F., Ebentheuer, J., et al. (2013). Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects. Neurosci. Lett. 532, 44-48. doi: 10.1016/j.neulet.2012.11.004.
215. Mollenhauer, B., Trenkwalder, C., von Ahsen, N., Bibl, M., Steinacker, P., Brechlin, P., et al. (2006). Beta-amlyoid 1-42 and tau-protein in cerebrospinal fluid of patients with Parkinson's disease dementia. Dement. Geriatr. Cogn. Disord. 22, 200-208. doi: 10.1159/000094871.
216. Mondello, S., Constantinescu, R., Zetterberg, H., Andreasson, U., Holmberg, B., and Jeromin, A. (2014). CSF α-synuclein and UCH-L1 levels in Parkinson's disease and atypical parkinsonian disorders. Parkinsonism Relat. Disord. 20, 382-387. doi: 10.1016/j.parkreldis.2014.01.011.
217. Mones, R. J. (1973). An analysis of six patients with Parkinson's disease who have been unresponsive to L-dopa therapy. J. Neurol. Neurosurg. Psychiatry 36, 362-367. doi: 10.1136/jnnp.36.3.362.
218. Mones, R. J., Wilk, S., Green, J., and Jutkowitz, R. (1972). A study of spinal fluid homovanillic acid (HVA) in patients with diseases of the nervous system. Mt. Sinai J. Med. 39, 478-485.
219. Montine, T. J., Shi, M., Quinn, J. F., Peskind, E. R., Craft, S., Ginghina, C., et al. (2010). CSF Aβ(42) and tau in Parkinson's disease with cognitive impairment. Mov. Disord. 25, 2682-2685. doi: 10.1002/mds.23287.
220. Moser, A., and Kömpf, D. (1992). Presence of methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinolines, derivatives of the neurotoxin isoquinoline, in parkinsonian lumbar CSF. Life Sci. 50, 1885-1891. doi: 10.1016/0024-3205(92)90549-5.
221. Moser, A., Scholz, J., Nobbe, F., Vieregge, P., Böhme, V., and Bamberg, H. (1995). Presence of N-methyl-norsalsolinol in the CSF: correlations with dopamine metabolites of patients with Parkinson's disease. J. Neurol. Sci. 131, 183-189. doi: 10.1016/0022-510X(95)00110-N.
222. Moser, A., Siebecker, F., Vieregge, P., Jaskowski, P., and Kömpf, D. (1996). Salsolinol, catecholamine metabolites, and visual hallucinations in L-dopa treated patients with Parkinson's disease. J. Neural Transm. 103, 421-432. doi: 10.1007/BF01276418.
223. Moussa, Z., Raftopoulos, C., Przedborski, S., and Hildebrand, J. (1992). Lack of changes in ventricular cerebrospinal fluid concentrations of homovanillic acid following acute challenge with levodopa. Ann. Neurol. 31, 113-115. doi: 10.1002/ana.410310124.
224. Müller, T., Blum-Degen, D., Przuntek, H., and Kuhn, W. (1998). Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease. Acta Neurol. Scand. 98, 142-144. doi: 10.1111/j.1600-0404.1998.tb01736.x.
225. Müller, T., Przuntek, H., Kuhn, W., Baum, S. S., and Rommelspacher, H. (1999a). No increase of synthesis of (R)salsolinol in Parkinson's disease. Mov. Disord. 14, 514-515.
226. Müller, T., Sällström Baum, S., Häussermann, P., Przuntek, H., Rommelspacher, H., and Kuhn, W. (1999b). R-and S-salsolinol are not increased in cerebrospinal fluid of Parkinsonian patients. J. Neurol. Sci. 164, 158-162. doi: 10.1016/S0022-510X(99)00058-1.
227. Naoi, M., and Maruyama, W. (1999). N-methyl(R)salsolinol, a dopamine neurotoxin, in Parkinson's disease. Adv. Neurol. 80, 259-264.
228. Nappi, G., Petraglia, F., Martignoni, E., Facchinetti, F., Bono, G., and Genazzani, A. R. (1985). beta-Endorphin cerebrospinal fluid decrease in untreated parkinsonian patients. Neurology 35, 1371-1374. doi: 10.1212/WNL.35.9.1371.
229. Nasr, A., Bertrand, N., Giroud, M., Septien, L., Gras, P., Dumas, R., et al. (1993). Cerebrospinal fluid choline levels in Parkinson's disease. Ann. Neurol. 34, 114-115. doi: 10.1002/ana.410340122.
230. Navarro, J. A., Jiménez-Jiménez, F. J., Molina, J. A., Benito-León, J., Cisneros, E., Gasalla, T., et al. (1998). Cerebrospinal fluid cyclic guanosine 3'5' monophosphate levels in Parkinson's disease. J. Neurol. Sci. 155, 92-94. doi: 10.1016/S0022-510X(97)00267-0.
231. Nielsen, H. M., Hall, S., Surova, Y., Nägga, K., Nilsson, C., Londos, E., et al. (2014). Low levels of soluble NG2 in cerebrospinal fluid from patients with dementia with Lewy bodies. J. Alzheimers Dis. 40, 343-350. doi: 10.3233/JAD-132246.
232. Nishi, K., Kondo, T., Narabayashi, H., Takubo, H., Muramoto, S., and Araki, H. (1989). Unresponsiveness to L-DOPA in parkinsonian patients: a study of homovanillic acid concentration in the cerebrospinal fluid. J. Neurol. Sci. 92, 65-70. doi: 10.1016/0022-510X(89)90175-5.
233. Nutu, M., Bourgeois, P., Zetterberg, H., Portelius, E., Andreasson, U., Parent, S., et al. (2013b). Aβ1-15/16 as a potential diagnostic marker in neurodegenerative diseases. Neuromolecular Med. 15, 169-179. doi: 10.1007/s12017-012-8208-8.
234. Nutu, M., Zetterberg, H., Londos, E., Minthon, L., Nägga, K., Blennow, K., et al. (2013a). Evaluation of the cerebrospinal fluid amyloid-β1-42/amyloid-β1-40 ratio measured by alpha-LISA to distinguish Alzheimer's disease from other dementia disorders. Dement. Geriatr. Cogn. Disord. 36, 99-110. doi: 10.1159/000353442.
235. Oeckl, P., Steinacker, P., Lehnert, S., Jesse, S., Kretzschmar, H. A., Ludolph, A. C., et al. (2012). CSF concentrations of cAMP and cGMP are lower in patients with Creutzfeldt-Jakob disease but not Parkinson's disease and amyotrophic lateral sclerosis. PLoS ONE 7:e32664. doi: 10.1371/journal.pone.0032664.
236. Ohrfelt, A., Grognet, P., Andreasen, N., Wallin, A., Vanmechelen, E., Blennow, K., et al. (2009). Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci. Lett. 450, 332-335. doi: 10.1016/j.neulet.2008.11.015.
237. Olsson, B., Constantinescu, R., Holmberg, B., Andreasen, N., Blennow, K., and Zetterberg, H. (2013). The glial marker YKL-40 is decreased in synucleinopathies. Mov. Disord. 28, 1882-1885. doi: 10.1002/mds.25589.
238. Olsson, J. E., Forsling, M. L., Lindvall, B., and Akerlund, M. (1987). Cerebrospinal fluid arginine vasopressin in Parkinson's disease, dementia, and other degenerative disorders. Adv. Neurol. 45, 239-242.
239. Olsson, R., and Roos, B. E. (1968). Concentrations of 5-hydroxyindoleacetic acid and homovanillic acid in the cerebrospinal fluid after treatment with probenecid in patients with Parkinson's disease. Nature 219, 502-503. doi: 10.1038/219502a0.
240. Paik, M. J., Ahn, Y. H., Lee, P. H., Kang, H., Park, C. B., Choi, S., et al. (2010). Polyamine patterns in the cerebrospinal fluid of patients with Parkinson's disease and multiple system atrophy. Clin. Chim. Acta 411, 1532-1535. doi: 10.1016/j.cca.2010.05.034.
241. Pålhagen, S., Qi, H., Mårtensson, B., Wålinder, J., Granérus, A. K., and Svenningsson, P. (2010). Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson's disease and major depression. J. Neurol. 257, 524-532. doi: 10.1007/s00415-009-5353-6.
242. Pall, H. S., Brailsford, S., Williams, A. C., Lunec, J., and Blake, D. R. (1990). Ferritin in the cerebrospinal fluid of patients with Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 53, 803. doi: 10.1136/jnnp.53.9.803.
243. Pall, H. S., Williams, A. C., Blake, D. R., Lunec, J., Gutteridge, J. M., Hall, M., et al. (1987). Raised cerebrospinal-fluid copper concentration in Parkinson's disease. Lancet 2, 238-241. doi: 10.1016/S0140-6736(87)90827-0.
244. Pan, B. Y., Cheng, Q. L., He, Z. X., and Su, C. C. (1997). "Transition metals in serum and CSF of patients with Parkinson's disease," in Poster P125, XIIth International Symposium on Parkinson's disease, London, March 23-26. Mov. Disord. 12(Suppl. 1), 33.
245. Pankonin, M. S., Sohi, J., Kamholz, J., and Loeb, J. A. (2009). Differential distribution of neuregulin in human brain and spinal fluid. Brain Res. 1258, 1-11. doi: 10.1016/j.brainres.2008.12.047.
246. Papeschi, R., Molina-Negro, P., Sourkes, T. L., and Erba, G. (1972). The concentration of homovanillic and 5-hydroxyindoleacetic acids in ventricular and lumbar CSF. Studies in patients with extrapyramidal disorders, epilepsy, and other diseases. Neurology 22, 1151-1159. doi: 10.1212/WNL.22.11.1151.
247. Papeschi, R., Molina-Negro, P., Sourkes, T. L., Hardy, J., and Bertrand, C. (1970). Concentration of homovanillic acid in the ventricular fluid of patients with Parkinson's disease and other dyskinesias. Neurology 20, 991-995. doi: 10.1212/WNL.20.10.991.
248. Park, M. J., Cheon, S. M., Bae, H. R., Kim, S. H., and Kim, J. W. (2011). Elevated levels of α-synuclein oligomer in the cerebrospinal fluid of drug-naïve patients with Parkinson's disease. J. Clin. Neurol. 7, 215-222. doi: 10.3988/jcn.2011.7.4.215.
249. Parnetti, L., Chiasserini, D., Bellomo, G., Giannandrea, D., De Carlo, C., Qureshi, M. M., et al. (2011). Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias. Mov. Disord. 26, 1428-1435. doi: 10.1002/mds.23670.
250. Parnetti, L., Chiasserini, D., Persichetti, E., Eusebi, P., Varghese, S., Qureshi, M. M., et al. (2014a). Cerebrospinal fluid lysosomal enzymes and α-synuclein in Parkinson's disease. Mov. Disord. 29, 1019-1027. doi: 10.1002/mds.25772.
251. Parnetti, L., Farotti, L., Eusebi, P., Chiasserini, D., De Carlo, C., Giannandrea, D., et al. (2014b). Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease. Front. Aging Neurosci. 6:53. doi: 10.3389/fnagi.2014.00053.
252. Parnetti, L., Tiraboschi, P., Lanari, A., Peducci, M., Padiglioni, C., D'Amore, C., et al. (2008). Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol. Psychiatry 64, 850-855. doi: 10.1016/j.biopsych.2008.02.016.
253. Perschak, H., Amsler, U., Vischer, A., Siegfried, J., and Cuénod, M. (1987). Ventricular cerebrospinal fluid concentrations of putative amino acid transmitters in Parkinson's disease and other disorders. Hum. Neurobiol. 6, 191-194.
254. Pezzoli, G., Panerai, A. E., Di Giulio, A., Longo, A., Passerini, D., and Carenzi, A. (1984). Methionine-enkephalin, substance P, and homovanillic acid in the CSF of parkinsonian patients. Neurology 34, 516-519. doi: 10.1212/WNL.34.4.516.
255. Pirttila, T., Mehta, P. D., Frey, H., and Wisniewski, H. M. (1994). Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease. Neurobiol. Aging 15, 313-317.
256. Pisani, A., Fezza, F., Galati, S., Battista, N., Napolitano, S., Finazzi-Agrò, A., et al. (2005). High endogenous cannabinoid levels in the cerebrospinal fluid of untreated Parkinson's disease patients. Ann. Neurol. 57, 777-779. doi: 10.1002/ana.20462.
257. Pisani, V., Moschella, V., Bari, M., Fezza, F., Galati, S., Bernardi, G., et al. (2010). Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients. Mov. Disord. 25, 920-924. doi: 10.1002/mds.23014.
258. Poewe, W., Benke, T., Karamat, E., Schelosky, L., Wagner, M., and Sperk, G. (1990). CSF somatostatin-like immunoreactivity in dementia of Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 53, 1105-1106. doi: 10.1136/jnnp.53.12.1105-a.
259. Prell, G. D., and Green, J. P. (1991). Histamine metabolites and pros-methylimidazoleacetic acid in human cerebrospinal fluid. Agents Actions Suppl. 33, 343-363.
260. Prell, G. D., Khandelwal, J. K., Burns, R. S., Blandina, P., Morrishow, A. M., and Green, J. P. (1991). Levels of pros-methylimidazoleacetic acid: correlation with severity of Parkinson's disease in CSF of patients and with the depletion of striatal dopamine and its metabolites in MPTP-treated mice. J. Neural Transm. Park. Dis. Dement. Sect. 3, 109-125. doi: 10.1007/BF02260886.
261. Přikrylová Vranová, H., Mareš, J., Hluštík, P., Nevrlý, M., Stejskal, D., Zapletalová, J., et al. (2012). Tau protein and beta-amyloid(1-42) CSF levels in different phenotypes of Parkinson's disease. J. Neural Transm. 119, 353-362. doi: 10.1007/s00702-011-0708-4.
262. Přikrylová Vranová, H., Mareš, J., Nevrlý, M., Stejskal, D., Zapletalová, J., Hluštík, P., et al. (2010). CSF markers of neurodegeneration in Parkinson's disease. J. Neural Transm. 117, 1177-1181. doi: 10.1007/s00702-010-0462-z.
263. Pullar, I. A., Dowson, J. H., Ahmed, R., Chow, R., and Gillingham, F. J. (1972). Biochemical investigations in Parkinsonism. A study of the metabolites of the biogenic amines in the lumbar CSF. Confin. Neurol. 34, 143-148 doi: 10.1159/000103047.
264. Qureshi, G. A., Baig, S., Bednar, I., Södersten, P., Forsberg, G., and Siden, A. (1995). Increased cerebrospinal fluid concentration of nitrite in Parkinson's disease. Neuroreport 6, 1642-1644. doi: 10.1097/00001756-199508000-00013.
265. Qureshi, G. A., Qureshi, A. A., Memon, S. A., and Parvez, S. H. (2006). Impact of selenium, iron, copper and zinc in on/off Parkinson's patients on L-dopa therapy. J. Neural Transm. Suppl. 71, 229-236. doi: 10.1007/978-3-211-33328-0_24.
266. Rainero, I., Kaye, J. A., May, C., Durso, R., Katz, D. I., Albert, M. L., et al. (1988). Alpha-melanocyte-stimulating hormonelike immunoreactivity is increased in cerebrospinal fluid of patients with Parkinson's disease. Arch. Neurol. 45, 1224-1227. doi: 10.1001/archneur.1988.00520350062017.
267. Rinne, U. K., Marttila, R., and Sonninen, V. (1977). Brain dopamine turnover and the relief of parkinsonism. Arch. Neurol. 34, 626-629. doi: 10.1001/archneur.1977.00500220060010.
268. Rinne, U. K., and Sonninen, V. (1972). Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's disease. Neurology 22, 62-67. doi: 10.1212/WNL.22.1.62.
269. Rinne, U. K., Sonninen, V., and Marttila, R. (1975). Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism. Adv. Neurol. 9, 383-392.
270. Rinne, U. K., Sonninen, V., and Siirtola, T. (1973). Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor. Eur. Neurol. 9, 349-362. doi: 10.1159/000114243.
271. Rota, E., Bellone, G., Rocca, P., Bergamasco, B., Emanuelli, G., and Ferrero, P. (2006). Increased intrathecal TGF-beta1, but not IL-12, IFN-gamma and IL-10 levels in Alzheimer's disease patients. Neurol. Sci. 27, 33-39. doi: 10.1007/s10072-006-0562-6.
272. Ruberg, M., Rieger, F., Villageois, A., Bonnet, A. M., and Agid, Y. (1986). Acetylcholinesterase and butyrylcholinesterase in frontal cortex and cerebrospinal fluid of demented and non-demented patients with Parkinson's disease. Brain Res. 362, 83-91. doi: 10.1016/0006-8993(86)91401-0.
273. Salehi, Z., and Mashayekhi, F. (2009). Brain-derived neurotrophic factor concentrations in the cerebrospinal fluid of patients with Parkinson's disease. J. Clin. Neurosci. 16, 90-93. doi: 10.1016/j.jocn.2008.03.010.
274. Selley, M. L. (1998). (E)-4-hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson's disease. Free Radic. Biol. Med. 25, 169-174. doi: 10.1016/S0891-5849(98)00021-5.
275. Sharpless, N. S., Thal, L. J., Perlow, M. J., Tabaddor, K., Waltz, J. M., Shapiro, K. N., et al. (1984). Vasoactive intestinal peptide in cerebrospinal fluid. Peptides 5, 429-433. doi: 10.1016/0196-9781(84)90248-1.
276. Shi, M., Bradner, J., Hancock, A. M., Chung, K. A., Quinn, J. F., Peskind, E. R., et al. (2011). Cerebrospinal fluid biomarkers for Parkinson's disease diagnosis and progression. Ann. Neurol. 69, 570-580. doi: 10.1002/ana.22311.
277. Shi, M., Furay, A. R., Sossi, V., Aasly, J. O., Armaly, J., Wang, Y., et al. (2012). DJ-1 and αSYN in LRRK2 CSF do not correlate with striatal dopaminergic function. Neurobiol. Aging 33, 836e5-e7. doi: 10.1016/j.neurobiolaging.2011.09.015.
278. Shukla, R., Rajani, M., Srivastava, N., Barthwal, M. K., and Dikshit, M. (2006). Nitrite and malondialdehyde content in cerebrospinal fluid of patients with Parkinson's disease. Int. J. Neurosci. 116, 1391-1402. doi: 10.1080/00207450500513989.
279. Siderowf, A., Xie, S. X., Hurtig, H., Weintraub, D., Duda, J., Chen-Plotkin, A., et al. (2010). CSF amyloid {beta} 1-42 predicts cognitive decline in Parkinson disease. Neurology 75, 1055-1061. doi: 10.1212/WNL.0b013e3181f39a78.
280. Sirviö, J., Soininen, H. S., Kutvonen, R., Hyttinen, J. M., Helkala, E. L., and Riekkinen, P. J. (1987). Acetyl-and butyrylcholinesterase activity in the cerebrospinal fluid of patients with Parkinson's disease. J. Neurol. Sci. 81, 273-279. doi: 10.1016/0022-510X(87)90102-X.
281. Sjögren, M., Davidsson, P., Wallin, A., Granérus, A. K., Grundström, E., Askmark, H., et al. (2002). Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement. Geriatr. Cogn. Disord. 13, 112-118. doi: 10.1159/000048642.
282. Steen, S. N., and Thomas, J. S. (1962). Glutamic oxaloacetic transaminase in serum and cerebrospinal fluid in parkinsonism. JAMA 180, 836-837. doi: 10.1001/jama.1962.03050230038017.
283. Stewart, T., Liu, C., Ginghina, C., Cain, K. C., Auinger, P., Cholerton, B., et al. (2014). Cerebrospinal fluid α-synuclein predicts cognitive decline in parkinson disease progression in the DATATOP cohort. Am. J. Pathol. 184, 966-975. doi: 10.1016/j.ajpath.2013.12.007.
284. Strittmatter, M. M., and Cramer, H. (1992). Parkinson's disease and dementia: clinical and neurochemical correlations. Neuroreport 3, 413-416. doi: 10.1097/00001756-199205000-00009.
285. Strittmatter, M., Hamann, G. F., Strubel, D., Cramer, H., and Schimrigk, K. (1996). Somatostatin-like immunoreactivity, its molecular forms and monoaminergic metabolites in aged and demented patients with Parkinson's disease-effect of L-Dopa. J. Neural Transm. 103, 591-602. doi: 10.1007/BF01273156.
286. Suemaru, S., Suemaru, K., Kawai, K., Miyata, S., Nobukuni, K., Ihara, Y., et al. (1995). Cerebrospinal fluid corticotropin-releasing hormone in neurodegenerative diseases: reduction in spinocerebellar degeneration. Life Sci. 57, 2231-2235. doi: 10.1016/0024-3205(95)02215-5.
287. Sundquist, J., Forsling, M. L., Olsson, J. E., and Akerlund, M. (1983). Cerebrospinal fluid arginine vasopressin in degenerative disorders and other neurological diseases. J. Neurol. Neurosurg. Psychiatry 46, 14-17. doi: 10.1136/jnnp.46.1.14.
288. Tabaddor, K., Wolfson, L. I., and Sharpless, N. S. (1978). Ventricular fluid homovanillic acid and 5-hydroxyindoleacetic acid concentrations in patients with movement disorders. Neurology 28, 1249-1253. doi: 10.1212/WNL.28.12.1249.
289. Takahashi, S., Takahashi, J., Osawa, N., Abe, T., Yonezawa, H., Sera, K., et al. (1994). [Trace elements analysis of serum and cerebrospinal fluid with PIXE-effect of age and changes in parkinsonian patients]. Nihon Ronen Igakkai Zasshi 31, 865-871. doi: 10.3143/geriatrics.31.865.
290. Tateno, F., Sakakibara, R., Kawai, T., Kishi, M., and Murano, T. (2012). Alpha-synuclein in the cerebrospinal fluid differentiates synucleinopathies (Parkinson Disease, dementia with Lewy bodies, multiple system atrophy) from Alzheimer disease. Alzheimer Dis. Assoc. Disord. 26, 213-216. doi: 10.1097/WAD.0b013e31823899cc.
291. Teelken, A. W., van den Berg, G. A., Muskiet, F. A., Staal-Schreinemachers, A. L., Wolthers, B. G., and Lakke, J. P. (1989). Catecholamine metabolism during additional administration of DL-threo-3,4-dihydroxyphenylserine to patients with Parkinson's disease. J. Neural Transm. Park. Dis. Dement. Sect. 1, 177-188. doi: 10.1007/BF02248667.
292. Teychenné, P. F., Ziegler, M. G., Lake, C. R., and Enna, S. J. (1982). Low CSF GABA in Parkinsonian patients who respond poorly to therapy or suffer from the "on-off" phenomenon. Ann. Neurol. 11, 76-79. doi: 10.1002/ana.410110113.
293. Tohgi, H., Abe, T., Hashiguchi, K., Takahashi, S., Nozaki, Y., and Kikuchi, T. (1991c). A significant reduction of putative transmitter amino acids in cerebrospinal fluid of patiens with Parkinson's disease and spinocerebellar degeneration. Neurosci. Lett. 126, 155-158. doi: 10.1016/0304-3940(91)90542-2.
294. Tohgi, H., Abe, T., Kikuchi, T., Takahashi, S., and Nozaki, Y. (1991a). The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson's disease. Neurosci. Lett. 132, 19-22. doi: 10.1016/0304-3940(91)90422-P.
295. Tohgi, H., Abe, T., Saheki, M., Hamato, F., Sasaki, K., and Takahashi, S. (1995b). Reduced and oxidized forms of glutathione and alpha-tocopherol in the cerebrospinal fluid of parkinsonian patients: comparison between before and after L-dopa treatment. Neurosci. Lett. 184, 21-24. doi: 10.1016/0304-3940(94)11158-F.
296. Tohgi, H., Abe, T., Saheki, M., Yamazaki, K., and Murata, T. (1997). Concentration of catecholamines and indoleamines in the cerebrospinal fluid of patients with vascular parkinsonism compared to Parkinson's disease patients. J. Neural Transm. 104, 441-449. doi: 10.1007/BF01277662.
297. Tohgi, H., Abe, T., and Takahashi, S. (1993d). The effects of L-threo-3,4-dihydroxyphenylserine on the total norepinephrine and dopamine concentrations in the cerebrospinal fluid and freezing gait in parkinsonian patients. J. Neural Transm. Park. Dis. Dement. Sect. 5, 27-34. doi: 10.1007/BF02260912.
298. Tohgi, H., Abe, T., Takahashi, S., and Kikuchi, T. (1993e). The urate and xanthine concentrations in the cerebrospinal fluid in patients with vascular dementia of the Binswanger type, Alzheimer type dementia, and Parkinson's disease. J. Neural Transm. Park. Dis. Dement. Sect. 6, 119-126. doi: 10.1007/BF02261005.
299. Tohgi, H., Abe, T., Takahashi, S., Nozaki, Y., and Kikuchi, T. (1991b). Concentrations of tyrosine, L-dihydroxyphenylalanine, dopamine, and 3-O-methyldopa in the cerebrospinal fluid of Parkinson's disease. Neurosci. Lett. 127, 212-214. doi: 10.1016/0304-3940(91)90796-V.
300. Tohgi, H., Abe, T., Takahashi, S., Takahashi, J., and Hamato, H. (1993b). Concentrations of serotonin and its related substances in the cerebrospinal fluid of parkinsonian patients and their relations to the severity of symptoms. Neurosci. Lett. 150, 71-74. doi: 10.1016/0304-3940(93)90111-W.
301. Tohgi, H., Abe, T., Takahashi, S., Takahashi, J., and Hamato, H. (1993c). Alterations in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration. Neurosci. Lett. 159, 135-138. doi: 10.1016/0304-3940(93)90817-5.
302. Tohgi, H., Abe, T., Takahashi, S., Takahashi, J., Nozaki, Y., Ueno, M., et al. (1993a). Monoamine metabolism in the cerebrospinal fluid in Parkinson's disease: relationship to clinical symptoms and subsequent therapeutic outcomes. J. Neural Transm. Park. Dis. Dement. Sect. 5, 17-26. doi: 10.1007/BF02260911.
303. Tohgi, H., Abe, T., Takahashi, S., Takahashi, J., Ueno, M., and Nozaki, Y. (1990). Effect of a synthetic norepinephrine precursor, L-threo-3,4-dihydroxyphenylserine on the total norepinephrine concentration in the cerebrospinal fluid of parkinsonian patients. Neurosci. Lett. 116, 194-197. doi: 10.1016/0304-3940(90)90409-3.
304. Tohgi, H., Abe, T., Yamazaki, K., Saheki, M., Takahashi, S., and Tsukamoto, Y. (1995a). Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. Neurosci. Lett. 192, 165-168. doi: 10.1016/0304-3940(95)11636-B.
305. Tokuda, T., Qureshi, M. M., Ardah, M. T., Varghese, S., Shehab, S. A., Kasai, T., et al. (2010). Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75, 1766-1772. doi: 10.1212/WNL.0b013e3181fd613b.
306. Tokuda, T., Salem, S. A., Allsop, D., Mizuno, T., Nakagawa, M., Qureshi, M. M., et al. (2006). Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochem. Biophys. Res. Commun. 349, 162-166. doi: 10.1016/j.bbrc.2006.08.024.
307. Trupp, M., Jonsson, P., Ohrfelt, A., Zetterberg, H., Obudulu, O., Malm, L., et al. (2014). Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease. J. Parkinsons Dis. 4, 549-560. doi: 10.3233/JPD-140389.
308. Turkka, J. T., Juujärvi, K. K., and Myllylä, V. V. (1987). Correlation of autonomic dysfunction to CSF concentrations of noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's disease. Eur. Neurol. 26, 29-34. doi: 10.1159/000116308.
309. van Dijk, K. D., Bidinosti, M., Weiss, A., Raijmakers, P., Berendse, H. W., and van de Berg, W. D. (2014). Reduced α-synuclein levels in cerebrospinal fluid in Parkinson's disease are unrelated to clinical and imaging measures of disease severity. Eur. J. Neurol. 21, 388-394. doi: 10.1111/ene.12176.
310. van Dijk, K. D., Jongbloed, W., Heijst, J. A., Teunissen, C. E., Groenewegen, H. J., Berendse, H. W., et al. (2013a). Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease. Parkinsonism Relat. Disord. 19, 1079-1083. doi: 10.1016/j.parkreldis.2013.07.016.
311. van Dijk, K. D., Persichetti, E., Chiasserini, D., Eusebi, P., Beccari, T., Calabresi, P., et al. (2013b). Changes in endolysosomal enzyme activities in cerebrospinal fluid of patients with Parkinson's disease. Mov. Disord. 28, 747-754. doi: 10.1002/mds.25495.
312. Van Sande, M., Caers, J., and Lowenthal, A. (1971). Cerebrospinal fluid amino acids in extrapyramidal disorders before and after L-DOPA treatment. Z. Neurol. 199, 24-29.
313. van Woert, M. H., and Bowers, M. B. Jr. (1970). Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease. Neurology 20, 377.
314. Vawter, M. P., Dillon-Carter, O., Tourtellotte, W. W., Carvey, P., and Freed, W. J. (1996). TGFbeta1 and TGFbeta2 concentrations are elevated in Parkinson's disease in ventricular cerebrospinal fluid. Exp. Neurol. 142, 313-322. doi: 10.1006/exnr.1996.0200.
315. Vermes, I., Steur, E. N., Jirikowski, G. F., and Haanen, C. (2004). Elevated concentration of cerebrospinal fluid tissue transglutaminase in Parkinson's disease indicating apoptosis. Mov. Disord. 19, 1252-1254. doi: 10.1002/mds.20197.
316. Vermes, I., Steur, E. N., Reutelingsperger, C., and Haanen, C. (1999). Decreased concentration of annexin V in parkinsonian cerebrospinal fluid: speculation on the underlying cause. Mov. Disord. 14, 1008-1010.
317. Volicer, L., Beal, M. F., Direnfeld, L. K., Marquis, J. K., and Albert, M. L. (1986). CSF cyclic nucleotides and somatostatin in Parkinson's disease. Neurology 36, 89-92. doi: 10.1212/WNL.36.1.89.
318. Volicer, L., Direnfeld, L. K., Freedman, M., Albert, M. L., Langlias, P. J., and Bird, E. D. (1985). Serotonin and 5-hydroxyindoleacetic acid in CSF. Difference in Parkinson's disease and dementia of the Alzheimer's type. Arch. Neurol. 42, 127-129. doi: 10.1001/archneur.1985.04060020037011.
319. Voto Bernales, J., Cruz, G. A., and Davila, E. (1973). [Determination of homovanillic acid in the cerebrospinal fluid of Parkinson's disease patients and control group]. Rev. Neuropsiquiatr. 36, 46-52 [Article in Spanish].
320. Vranová, H. P., Hényková, E., Kaiserová, M., Menšíková, K., Vaštík, M., Mareš, J., et al. (2014). Tau protein, beta-amyloid1-42 and clusterin CSF levels in the differential diagnosis of Parkinsonian syndrome with dementia. J. Neurol. Sci. 343, 102-104. doi: 10.1016/j.jns.2014.05.052.
321. Wang, E. S., Sun, Y., Guo, J. G., Gao, X., Hu, J. W., Zhou, L., et al. (2010). Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson's disease. Acta Neurol. Scand. 122, 350-359. doi: 10.1111/j.1600-0404.2009.01318.x.
322. Wang, Y., Hancock, A. M., Bradner, J., Chung, K. A., Quinn, J. F., Peskind, E. R., et al. (2011). Complement 3 and factor h in human cerebrospinal fluid in Parkinson's disease, Alzheimer's disease, and multiple-system atrophy. Am. J. Pathol. 178, 1509-1516. doi: 10.1016/j.ajpath.2011.01.006.
323. Wang, Y., Shi, M., Chung, K. A., Zabetian, C. P., Leverenz, J. B., Berg, D., et al. (2012). Phosphorylated α-synuclein in Parkinson's disease. Sci. Transl. Med. 4, 121ra20. doi: 10.1126/scitranslmed.3002566.
324. Waragai, M., Wei, J., Fujita, M., Nakai, M., Ho, G. J., Masliah, E., et al. (2006). Increased level of DJ-1 in the cerebrospinal fluids of sporadic Parkinson's disease. Biochem. Biophys. Res. Commun. 345, 967-972. doi: 10.1016/j.bbrc.2006.05.011.
325. Weiner, W. J., and Klawans, H. L. Jr. (1973). Failure of cerebrospinal fluid homovanillic acid to predict levodopa response in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 36, 747-752. doi: 10.1136/jnnp.36.5.747.
326. Weiner, W., Harrison, W., and Klawans, H. (1969). L-dopa and cerebrospinal fluid homovanillic acid in Parkinsonism. Life Sci. 8, 971-976. doi: 10.1016/0024-3205(69)90428-7.
327. Weiss, J., Gründig, E., and Gerstenbrand, F. (1975). [The activity of aminotransferases in serum and cerebrospinal fluid in neurological diseases (author's transl)]. Wien. Klin. Wochenschr. 87, 799-803.
328. Welch, M. J., Markham, C. H., and Jenden, D. J. (1976). Acetylcholine and choline in cerebrospinal fluid of patients with Parkinson's disease and Huntington's chorea. J. Neurol. Neurosurg. Psychiatry 39, 367-374. doi: 10.1136/jnnp.39.4.367.
329. Wennström, M., Surova, Y., Hall, S., Nilsson, C., Minthon, L., Boström, F., et al. (2013). Low CSF levels of both α-synuclein and the α-synuclein cleaving enzyme neurosin in patients with synucleinopathy. PLoS ONE 8:e53250. doi: 10.1371/journal.pone.0053250.
330. Widner, B., Leblhuber, F., and Fuchs, D. (2002). Increased neopterin production and tryptophan degradation in advanced Parkinson's disease. J. Neural Transm. 109, 181-189. doi: 10.1007/s007020200014.
331. Wienecke, M., Werth, E., Poryazova, R., Baumann-Vogel, H., Bassetti, C. L., Weller, M., et al. (2012). Progressive dopamine and hypocretin deficiencies in Parkinson's disease: is there an impact on sleep and wakefulness? J. Sleep Res. 21, 710-717. doi: 10.1111/j.1365-2869.2012.01027.x.
332. Wilk, S., and Mones, R. (1971). Cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylethylene glycol in Parkinsonism before and after treatment with L-dopa. J. Neurochem. 18, 1771-1773. doi: 10.1111/j.1471-4159.1971.tb03753.x.
333. Williams, A., Ballenger, J., Levine, R., Lovenberg, W., and Calne, D. (1980b). Aging and CSF hydroxylase cofactor. Neurology 30, 1244-1246. doi: 10.1212/WNL.30.11.1244.
334. Williams, A. C., Levine, R. A., Chase, T. N., Lovenberg, W., and Calne, D. B. (1980a). CFS hydroxylase cofactor levels in some neurological diseases. J. Neurol. Neurosurg. Psychiatry 43, 735-738. doi: 10.1136/jnnp.43.8.735.
335. Woulfe, J. M., Duke, R., Middeldorp, J. M., Stevens, S., Vervoort, M., Hashimoto, M., et al. (2002). Absence of elevated anti-alpha-synuclein and anti-EBV latent membrane protein antibodies in PD. Neurology 58, 1435-1436. doi: 10.1212/WNL.58.9.1435.
336. Yaksh, T. L., Carmichael, S. W., Stoddard, S. L., Tyce, G. M., Kelly, P. J., Lucas, D., et al. (1990). Measurement of lumbar CSF levels of met-enkephalin, encrypted met-enkephalin, and neuropeptide Y in normal patients and in patients with Parkinson's disease before and after autologous transplantation of adrenal medulla into the caudate nucleus. J. Lab. Clin. Med. 115, 346-351.
337. Yamada, H., Otsuka, M., Fujimoto, K., Kawashima, K., and Yoshida, M. (1996). Determination of acetylcholine concentration in cerebrospinal fluid of patients with neurologic diseases. Acta Neurol. Scand. 93, 76-78. doi: 10.1111/j.1600-0404.1996.tb00175.x.
338. Yamada, T., Chong, J. K., Asahina, M., Koguchi, Y., and Hirayama, K. (1993). Concentration of neural thread protein in cerebrospinal fluid from progressive supranuclear palsy and Parkinson's disease. Jpn. J. Psychiatry Neurol. 47, 631-635.
339. Yamada, T., Moroo, I., Koguchi, Y., Asahina, M., and Hirayama, K. (1994). Increased concentration of C4d complement protein in the cerebrospinal fluids in progressive supranuclear palsy. Acta Neurol. Scand. 89, 42-46. doi: 10.1111/j.1600-0404.1994.tb01631.x.
340. Yamamoto, M., Ogawa, N., and Ujike, H. (1986). Effect of L-threo-3,4-dihydroxyphenylserine chronic administration on cerebrospinal fluid and plasma free 3-methoxy-4-hydroxy-phenylglycol concentration in patients with Parkinson's disease. J. Neurol. Sci. 73, 39-44. doi: 10.1016/0022-510X(86)90061-4.
341. Yamamoto-Watanabe, Y., Watanabe, M., Jackson, M., Akimoto, H., Sugimoto, K., Yasujima, M., et al. (2010). Quantification of cystatin C in cerebrospinal fluid from various neurological disorders and correlation with G73A polymorphism in CST3. Brain Res. 1361, 140-145. doi: 10.1016/j.brainres.2010.09.033.
342. Yasui, K., Inoue, Y., Kanbayashi, T., Nomura, T., Kusumi, M., and Nakashima, K. (2006). CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration. J. Neurol. Sci. 250, 120-123. doi: 10.1016/j.jns.2006.08.004.
343. Yoshinaga, J., Sasaki, T., Ideshita, H., Hikiji, A., and Kuwaki, T. (1989). Acetylcholinesterase activity in CSF in senile dementia of Alzheimer type, vascular dementia, and Parkinson's disease. Rinsho Shinkeigaku 29, 376-378.
344. Zhang, J., Mattison, H. A., Liu, C., Ginghina, C., Auinger, P., McDermott, M. P., et al. (2013). Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathol. 126, 671-682. doi: 10.1007/s00401-013-1121-x.
345. Zhang, J., Sokal, I., Peskind, E. R., Quinn, J. F., Jankovic, J., Kenney, C., et al. (2008). CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. Am. J. Clin. Pathol. 129, 526-529. doi: 10.1309/W01Y0B808EMEH12L.
346. Zhou, G., Shoji, H., Yamada, S., and Matsuishi, T. (1997). Decreased beta-phenylethylamine in CSF in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 63, 754-758. doi: 10.1136/jnnp.63.6.754.
347. Zubenko, G. S., Marquis, J. K., Volicer, L., Direnfeld, L. K., Langlais, P. J., and Nixon, R. A. (1986). Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study. Biol. Psychiatry 21, 1365-1381. doi: 10.1016/0006-3223(86)90328-8.
348. Zubenko, G. S., Volicer, L., Direnfeld, L. K., Freeman, M., Langlais, P. J., and Nixon, R. A. (1985). Cerebrospinal fluid levels of angiotensin-converting enzyme in Alzheimer's disease, Parkinson's disease and progressive supranuclear palsy. Brain Res. 328, 215-221. doi: 10.1016/0006-8993(85)91032-7.